
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="ABCBAB67926532A33DAB670039FB518E.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cancers">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cancers">
<meta name="citation_title" content="The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer">
<meta name="citation_author" content="Karam Khaddour">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA">
<meta name="citation_author" content="Manuel Felipe Fernandez">
<meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA">
<meta name="citation_author" content="Marsel Khabibov">
<meta name="citation_author_institution" content="I. M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia">
<meta name="citation_author" content="Airat Garifullin">
<meta name="citation_author_institution" content="P. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia">
<meta name="citation_author" content="Danielle Dressler">
<meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA">
<meta name="citation_author" content="Iuliia Topchu">
<meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA">
<meta name="citation_author" content="Jyoti D Patel">
<meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA">
<meta name="citation_author" content="Frank Weinberg">
<meta name="citation_author_institution" content="Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA">
<meta name="citation_author" content="Yanis Boumber">
<meta name="citation_author_institution" content="Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA">
<meta name="citation_author_institution" content="Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420012 Kazan, Russia">
<meta name="citation_publication_date" content="2022 Oct 28">
<meta name="citation_volume" content="14">
<meta name="citation_issue" content="21">
<meta name="citation_firstpage" content="5305">
<meta name="citation_doi" content="10.3390/cancers14215305">
<meta name="citation_pmid" content="36358724">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/pdf/cancers-14-05305.pdf">
<meta name="description" content="DNA-damage repair (DDR) gene alterations are a hallmark for cancer. The exploitation of DDR alterations has improved outcomes in breast, ovarian, pancreatic, and prostate cancers. However, little is known about the role of DDR alterations, leading ...">
<meta name="og:title" content="The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="DNA-damage repair (DDR) gene alterations are a hallmark for cancer. The exploitation of DDR alterations has improved outcomes in breast, ovarian, pancreatic, and prostate cancers. However, little is known about the role of DDR alterations, leading ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Searchâ€¦
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="9654807">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/cancers14215305"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/cancers-14-05305.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9654807%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/9654807/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/9654807/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cancers.png" alt="Cancers logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cancers" title="Link to Cancers" shape="default" href="http://www.mdpi.com/journal/cancers" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cancers (Basel)</button></div>. 2022 Oct 28;14(21):5305. doi: <a href="https://doi.org/10.3390/cancers14215305" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/cancers14215305</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Cancers%20(Basel)%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cancers%20(Basel)%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cancers%20(Basel)%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cancers%20(Basel)%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khaddour%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Karam Khaddour</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Karam Khaddour</span></h3>
<div class="p">
<sup>1</sup>Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khaddour%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Karam Khaddour</span></a>
</div>
</div>
<sup>1,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Felipe%20Fernandez%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Manuel Felipe Fernandez</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Manuel Felipe Fernandez</span></h3>
<div class="p">
<sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Felipe%20Fernandez%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Manuel Felipe Fernandez</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khabibov%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Marsel Khabibov</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Marsel Khabibov</span></h3>
<div class="p">
<sup>3</sup>I. M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Khabibov%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marsel Khabibov</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garifullin%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Airat Garifullin</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Airat Garifullin</span></h3>
<div class="p">
<sup>4</sup>P. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garifullin%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Airat Garifullin</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dressler%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Danielle Dressler</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Danielle Dressler</span></h3>
<div class="p">
<sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dressler%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Danielle Dressler</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Topchu%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Iuliia Topchu</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Iuliia Topchu</span></h3>
<div class="p">
<sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Topchu%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Iuliia Topchu</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20JD%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Jyoti D Patel</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Jyoti D Patel</span></h3>
<div class="p">
<sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Patel%20JD%22%5BAuthor%5D" class="usa-link"><span class="name western">Jyoti D Patel</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weinberg%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Frank Weinberg</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Frank Weinberg</span></h3>
<div class="p">
<sup>1</sup>Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weinberg%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Frank Weinberg</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Boumber%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Yanis Boumber</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Yanis Boumber</span></h3>
<div class="p">
<sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA</div>
<div class="p">
<sup>5</sup>Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420012 Kazan, Russia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Boumber%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yanis Boumber</span></a>
</div>
</div>
<sup>2,</sup><sup>5,</sup><sup>*</sup>
</div>
<div class="cg p">Editor: <span class="name western">Andrea Cavazzoni</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-cancers-14-05305">
<sup>1</sup>Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL 60612, USA</div>
<div id="af2-cancers-14-05305">
<sup>2</sup>Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA</div>
<div id="af3-cancers-14-05305">
<sup>3</sup>I. M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia</div>
<div id="af4-cancers-14-05305">
<sup>4</sup>P. Hertsen Moscow Oncology Research Institute, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 125284 Moscow, Russia</div>
<div id="af5-cancers-14-05305">
<sup>5</sup>Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420012 Kazan, Russia</div>
<div class="author-notes p"><div class="fn" id="c1-cancers-14-05305">
<sup>*</sup><p class="display-inline">Correspondence: <span>kkhadd2@uic.edu</span> (K.K.); <span>yanis.boumber@northwestern.edu</span> (Y.B.)</p>
</div></div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Andrea Cavazzoni</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2022 Sep 27; Accepted 2022 Oct 26; Collection date 2022 Nov.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Â© 2022 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC9654807Â Â PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36358724/" class="usa-link">36358724</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Simple Summary</h3>
<p>DNA-damage repair (DDR) gene alterations are a hallmark for cancer. The exploitation of DDR alterations has improved outcomes in breast, ovarian, pancreatic, and prostate cancers. However, little is known about the role of DDR alterations, leading to a homologous recombination deficiency (HRD) state in lung cancer. In this review, we discuss the existing literature examining the role of DDR alterations as both predictive biomarkers of response to therapy and as therapeutic targets in lung cancer.</p></section><section id="sec2"><h3 class="pmc_sec_title">Abstract</h3>
<p>Lung cancer remains the second most commonly diagnosed cancer worldwide and the leading cause of cancer-related mortality. The mapping of genomic alterations and their role in lung-cancer progression has been followed by the development of new therapeutic options. Several novel drugs, such as targeted therapy and immunotherapy, have significantly improved outcomes. However, many patients with lung cancer do not benefit from existing therapies or develop progressive disease, leading to increased morbidity and mortality despite initial responses to treatment. Alterations in DNA-damage repair (DDR) genes represent a cancer hallmark that impairs a cellâ€™s ability to prevent deleterious mutation accumulation and repair. These alterations have recently emerged as a therapeutic target in breast, ovarian, prostate, and pancreatic cancers. The role of DDR alterations remains largely unknown in lung cancer. Nevertheless, recent research efforts have highlighted a potential role of some DDR alterations as predictive biomarkers of response to treatment. Despite the failure of PARP inhibitors (main class of DDR targeting agents) to improve outcomes in lung cancer patients, there is some evidence suggesting a role of PARP inhibitors and other DDR targeting agents in benefiting a distinct subset of lung cancer patients. In this review, we will discuss the existing literature on DDR alterations and homologous recombination deficiency (HRD) state as predictive biomarkers and therapeutic targets in both non-small cell lung and small cell lung cancer.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> non-small cell lung cancer, small cell lung cancer, DNA-damage repair, homologous recombination deficiency, PARP</p></section></section><section id="sec1-cancers-14-05305"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Lung cancer represents a major healthcare burden despite the introduction of several novel effective medications that improves outcomes [<a href="#B1-cancers-14-05305" class="usa-link" aria-describedby="B1-cancers-14-05305">1</a>]. Globally, lung cancer is the leading cause of death for men (1.2 million deaths per year), and the second leading cause of death for women (576,100) among all cancers [<a href="#B2-cancers-14-05305" class="usa-link" aria-describedby="B2-cancers-14-05305">2</a>]. Lung cancer is divided histologically and clinically into non-small cell lung cancer (NSCLC) (approximately 85% of newly diagnosed lung cancer) and small cell lung cancer (SCLC) (approximately 15%). NSCLC is further classified into subcategories including adenocarcinoma (LUAD) and squamous cell lung carcinoma (LUSC), which have distinct molecular features, treatment approaches, and different prognoses. The treatment of NSCLC has been revolutionized with the introduction of several novel therapeutics such as targeted therapy and immunotherapy. Targeted therapy is indicated in patients with metastatic lung cancer whose tumors harbor an oncogenic driver mutation. However, approximately a third of patients with lung adenocarcinoma (LUAD) and the majority of LUSC and SCLC patients do not have targetable oncogenic driver mutations [<a href="#B3-cancers-14-05305" class="usa-link" aria-describedby="B3-cancers-14-05305">3</a>,<a href="#B4-cancers-14-05305" class="usa-link" aria-describedby="B4-cancers-14-05305">4</a>,<a href="#B5-cancers-14-05305" class="usa-link" aria-describedby="B5-cancers-14-05305">5</a>]. Moreover, several oncogenic driver mutations remain undruggable or only have medications approved in the second-line setting such as with <em>KRAS<sup>G12C</sup></em> inhibitors [<a href="#B6-cancers-14-05305" class="usa-link" aria-describedby="B6-cancers-14-05305">6</a>]. Patients with NSCLC without identifiable oncogenic driver alterations can be treated with either chemotherapy or chemoimmunotherapy, depending on the cancer subtype and programmed death-ligand 1 (PD-L1) expression. Despite the improvement in overall survival (OS) with the integration of immune checkpoint inhibitors (ICI) in early-stage and metastatic lung cancer, the benefit in OS appears to be driven by a subset of patients whose tumors have a high PD-L1 expression â‰¥ 50% [<a href="#B7-cancers-14-05305" class="usa-link" aria-describedby="B7-cancers-14-05305">7</a>,<a href="#B8-cancers-14-05305" class="usa-link" aria-describedby="B8-cancers-14-05305">8</a>]. Patients with PD-L1 expression levels 0% and 1â€“49% appear to have variable outcomes with modest benefit with immunotherapy alone, which is moderately improved with the use of chemoimmunotherapy [<a href="#B9-cancers-14-05305" class="usa-link" aria-describedby="B9-cancers-14-05305">9</a>]. As such, there is an unmet need to explore potential new effective therapeutic approaches to improve outcomes in NSCLC. Moreover, SCLC, which is considered a recalcitrant tumor, represents a challenge for patients and physicians given the lack of effective therapeutics and poor outcomes relative to other cancers. Recent advances in the ability to map genomic alterations in lung cancer have led to the identification of relevant targetable pathways and provided the means to study several biomarkers, which could help to select patients for specific treatments.</p>
<p>DNA-damage repair (DDR) pathways are essential for cellular integrity and high-fidelity genome repair that results from exogenous and endogenous DNA insults. They consist of multiple genes that are responsible for maintaining genomic stability by removing damaged DNA in a substrate-specific manner. Alterations in DDR pathways are an important hallmark for tumorigenesis, cancer progression and prognosis [<a href="#B10-cancers-14-05305" class="usa-link" aria-describedby="B10-cancers-14-05305">10</a>]. The analysis of The Cancer Genome Atlas (TCGA) in 33 cancer types demonstrated that mutations with loss of heterozygosity in various tumor types were observed in one third of DDR genes [<a href="#B10-cancers-14-05305" class="usa-link" aria-describedby="B10-cancers-14-05305">10</a>]. DDR pathways can be functionally classified into nucleotide excision repair (NER), base excision repair (BER), direct repair (DR), DNA double-stranded break repair including homologous recombination (HR) and non-homologous end joining (NHEJ), and mismatch repair (MMR) [<a href="#B11-cancers-14-05305" class="usa-link" aria-describedby="B11-cancers-14-05305">11</a>] (<a href="#cancers-14-05305-f001" class="usa-link">Figure 1</a>). These pathways work in a highly orchestrated manner to maintain genomic stability and prevent the accumulation of mutations leading to senescence, apoptosis or clonal cancerous evolution. NER is an important DNA repair pathway that consists of two sub-pathways (global genomic NER (GG-NER) and transcription-coupled NER (TC-NER)) [<a href="#B12-cancers-14-05305" class="usa-link" aria-describedby="B12-cancers-14-05305">12</a>]. DNA alterations that are primarily targeted by NER include bulky DNA adducts caused by UV light and chemotherapeutic agents such as platinum agents inducing interstrand crosslinks [<a href="#B12-cancers-14-05305" class="usa-link" aria-describedby="B12-cancers-14-05305">12</a>]. MMR is responsible for the repair of base substitution mismatches, insertionâ€“deletion mismatches, and DNA crosslinks. BER is responsible for the removal of small covalent modifications of DNA bases and requires five enzymatic activities: glycosylase, endonuclease, lyase, polymerase, and ligase. It includes two sub-pathways: short-patch (i.e., single-nucleotide) and long-patch BER (&gt;1 nucleotide) [<a href="#B13-cancers-14-05305" class="usa-link" aria-describedby="B13-cancers-14-05305">13</a>]. The endonuclease activity also leads to the single-strand break repair pathway, which stimulates the poly(ADP-ribose) activity of PARP1, which will be discussed later [<a href="#B11-cancers-14-05305" class="usa-link" aria-describedby="B11-cancers-14-05305">11</a>]. DNA double-strand breaks (DSBs) are induced by ionizing radiation, chemotherapeutic agents, faulty DNA replication, and oxidative stress. Two main pathways involved in the repair of DSBs include HR and NHEJ. Both BRCA1 and BRCA2 proteins interact with a variety of proteins involved in the HR pathway and appear to be essential to the process, acting at different stages of DSB repair [<a href="#B14-cancers-14-05305" class="usa-link" aria-describedby="B14-cancers-14-05305">14</a>].</p>
<figure class="fig xbox font-sm" id="cancers-14-05305-f001"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9654807_cancers-14-05305-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ac/9654807/aee6c2097072/cancers-14-05305-g001.jpg" loading="lazy" height="471" width="799" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/cancers-14-05305-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Summary of the six main mechanisms responsible for the DDR. (<strong>A</strong>) Mismatch repair: At the beginning of the process of the mismatch repair, mispaired bases are recognized by the sliding clamp MutSÎ± homolog (MSH2:MSH6). Subsequently, the MLH1:PMS2complex is recruited for the incision, followed by the excision of the damage by exonuclease-1, resulting in a gap, which is then filled by PolÎ´ and DNA ligase I. (<strong>B</strong>) BER: This pathway is responsible for the removal of small covalent modifications. These lesions are recognized by one of the specific DNA glycosylases and then hydrolyzed by AP-endonuclease (APE). PARP1 is recruited by nicked DNA due to APE1 and aid in DNA repair. If a single nucleotide is damaged, then the shortpatch BER pathway repairs it. The long-patch BER pathway is responsible for the repair of a lesion of at least two nucleotides. (<strong>C</strong>) Homologous recombination: This pathway is involved in the repair of the double-strand breaks and is carried out in late S and G2 phases when the homologous sister chromatid can be used as a template. In this process, ATM facilitates the activity of MRN complex at the site of DNA damage. The MRN complex then resects DNA from the dsDNA break site and the DNA strand is digested. As a result, single-stranded DNA is produced and RPA binds to it. BRCA1 and BRCA2 proteins (linked by PALB2 protein) control Rad51 that facilitates the search for a homologous DNA sequence and the formation of a D-loop. DNA polymerase eta finishes this process. (<strong>D</strong>) NHEJ: This pathway is involved in DSB repair but does not require a homologous template. Two free DNA ends are bound by Ku70/Ku80 heterodimer, DNA-PK is then utilized, and an active catalytic complex is formed. Subsequently, artemis endonuclease is also recruited for the endonucleolytic cleavage, then the Ligase IV/XRCC4 complex ligates DNA ends. A sub-pathway of NHEJ, which is an alternative end-joining, utilizes the Pol Î¸, PARP1 and MRN complex for DNA repair. (<strong>E</strong>) NER: This pathway is divided into two sub-pathways based on the DNA damage recognition step. Global genome nucleotide excision repair (GG-NER) detects and eliminates bulky DNA excisions throughout the genome, including non-transcribed regions and silent chromatin. In this pathway, XPC-RAD23B complex recognizes DNA lesions and recruits downstream factors. Transcription-coupled NER (TC-NER) operates when a transcribed DNA strand is damaged, limiting transcription activity. TC-NER is triggered by RNAPIIo-bound Cockayne Syndrome Group B (CSB) protein, which recruits CSA via the CSA-interaction motif (CIM). Once recruited, CSA facilitates UVSSAâ€™s association with stalled RNA Pol II (RNA P IIo). UVSSA is the key factor that recruits the TFIIH complex in response to CSB and CSA. TC-NER and GG-NER use the same mechanism after detecting damage. The TFIIH complex unwinds the DNA helix to obtain access to the pre-incision complex (XP family), allowing for RPA to be recruited. The damaged DNA is then excised, aided by XPG and the endonucleases excision repair cross-complementing enzyme group 1 (CPF-ERCC1). Then, the DNA gap is refilled by PCNA and RPC, followed by backbone repair via DNA ligase I. (<strong>F</strong>) Direct repair: The presence of the alkyl group at the O6 position of guanine causes G:C to A:T transitions. The direct repair functions through the removal of the alkyl group at the site of lesion by the enzyme O6-methylguanine DNA methyltransferase (MGMT), thus restoring the proper nucleotide.</p></figcaption></figure><p>Defects in the function of cell regulatory checkpoints can promote cancer growth through the accumulation of deleterious mutations [<a href="#B15-cancers-14-05305" class="usa-link" aria-describedby="B15-cancers-14-05305">15</a>]. The impact of DDR gene alterations on cancer formation is important in patients with hereditary cancer syndromes such as germline <em>BRCA1/2</em> pathologic mutation carriers who have a higher relative risk incidence of breast, ovarian, uterine, and pancreatic cancers. However, DDR-deficient tumors still require intact mechanisms to repair the DNA damage necessary for survival and shift dependence to other intact DNA repair pathways. As such, targeting these dependent pathways in DDR-deficient cancer cells leads to a synthetically lethal effect that can halt the growth of cancer cells [<a href="#B16-cancers-14-05305" class="usa-link" aria-describedby="B16-cancers-14-05305">16</a>]. This has been studied extensively in the preclinical and clinical setting in cancers harboring <em>BRCA1/2</em> mutations, which induce homologous recombination deficiency (HRD), leading to a reliance on other compensatory DDR pathways such as BER and NHEJ [<a href="#B17-cancers-14-05305" class="usa-link" aria-describedby="B17-cancers-14-05305">17</a>]. Alterations in homologous recombination pathway genes have been extensively studied in cancer, due to their high suitability for cancer hereditary syndromes in pathologic <em>BRCA1/2</em> germline mutation carriers. Most of the novel cancer therapies that are being developed to target DDR pathway involve inhibitors of homologous recombination genes. Therefore, HRD-scoring algorithms have been developed using different assays to allow for the quantification of the degree of genomic instability as multiple genes, in addition to <em>BRCA1/</em>2, play important roles in DNA repair. Several HRD scores were developed, which rely on algorithms pertaining to loss of heterozygosity (LOH), number of telomeric allelic imbalances (NtAI), and large-scale transitions (LST) [<a href="#B18-cancers-14-05305" class="usa-link" aria-describedby="B18-cancers-14-05305">18</a>,<a href="#B19-cancers-14-05305" class="usa-link" aria-describedby="B19-cancers-14-05305">19</a>,<a href="#B20-cancers-14-05305" class="usa-link" aria-describedby="B20-cancers-14-05305">20</a>]. In clinical trials, HRD-deficient ovarian and breast cancers due to <em>BRCA1/2</em> germline mutations rely on poly(ADP-ribose) polymerase (PARP) to repair single and double-stranded breaks. Therefore, targeting PARP enzymes with specific inhibitors leads to synthetic lethality and cancer cell death. The FDA and EMA have approved several PARP inhibitors (PARPi) that demonstrated clinical efficacy and acceptable safety in <em>BRCA1/2</em> mutated breast and ovarian cancers [<a href="#B21-cancers-14-05305" class="usa-link" aria-describedby="B21-cancers-14-05305">21</a>,<a href="#B22-cancers-14-05305" class="usa-link" aria-describedby="B22-cancers-14-05305">22</a>]. The clinical efficacy was evident in other cancer types due to <em>BRCA1/2</em> or other deleterious mutations in the HR pathway (such as <em>ATM</em>), specifically pancreatic and prostate cancers [<a href="#B23-cancers-14-05305" class="usa-link" aria-describedby="B23-cancers-14-05305">23</a>]. The activity of PARPi in certain cancers with deficient homologous recombination repair ability (mainly due to <em>BRCA1/2</em> mutations) was the first clinical demonstration of the role of exploiting HR alterations to improve outcomes and prolong survival in cancer patients. The benefit of targeting homologous recombination pathway alterations has been limited to a few cancers with specific molecular signatures due to dysfunction of the HR pathway (<em>BRCA1/2</em>, <em>ATM</em> and HRD state). The impact of possible DDR alterations (which entails more than 350 candidate genes) remains insufficiently explored in oncology. Recently, the term BRCAness was developed to refer to cancers that have the phenotype of <em>BRCA1/2</em> mutations due to non-BRCA DDR alterations, epigenetic modulation and post translational modification [<a href="#B16-cancers-14-05305" class="usa-link" aria-describedby="B16-cancers-14-05305">16</a>].</p>
<p>Research is ongoing regarding the impact of DDR alterations on cancer formation, progression and therapeutic potential in other cancer types, including lung cancer. The fact that alterations in DDR genes are detected in a third of cancers raises several questions regarding the role of such deficiencies in lung cancer. This is of importance as several drugs that target DDR alterations are currently being developed and studied. These include PARP inhibitors, inhibitors of ATR and ATM, inhibitors of CHK1/2, inhibitors of WEE1 and their combinations, including with one another, chemotherapy, targeted therapy, or immunotherapy [<a href="#B16-cancers-14-05305" class="usa-link" aria-describedby="B16-cancers-14-05305">16</a>]. Smoking, which is a major risk factor in lung cancer, induces DNA damage, promoting the activation of several repair mechanisms that could provide a rationale for targeting DDR defects in selected lung cancer patients [<a href="#B24-cancers-14-05305" class="usa-link" aria-describedby="B24-cancers-14-05305">24</a>,<a href="#B25-cancers-14-05305" class="usa-link" aria-describedby="B25-cancers-14-05305">25</a>,<a href="#B26-cancers-14-05305" class="usa-link" aria-describedby="B26-cancers-14-05305">26</a>]. However, despite the evidence that smoking-related lung cancer is associated with a higher somatic tumor mutation burden, it remains unclear if specific DDR gene alterations are more common in lung cancer that arises in smokers.</p>
<p>In this review, we discuss the current and previous literature regarding the role of DDR alterations (mainly HR) and HRD status in NSCLC and SCLC. We will discuss the frequency and pathological impact of DDR alterations in both types of lung cancer. Next, we will discuss the predictive and prognostic potential of DDR alterations as biomarkers for NSCLC and SCLC. Additionally, we will review the literature on the clinical relevance of targeting DDR alterations (mainly HR pathway) and the HRD phenotype of lung cancers.</p></section><section id="sec2-cancers-14-05305"><h2 class="pmc_sec_title">2. Frequency of DDR Alterations in Lung Cancer</h2>
<p>Heeke et al. studied the prevalence of HR-DDR deficiency across 21 tumor types including the following genes (<em>ARID1A</em>, <em>ATM</em>, <em>ATRX</em>, <em>BAP1</em>, <em>BARD1</em>, <em>BLM</em>, <em>BRCA1/2</em>, <em>BRIP1</em>, <em>CHEK1/2</em>, <em>FANCA/C/D2/E/F/G/L</em>, <em>MRE11A</em>, <em>NBN</em>, <em>PALB2</em>, <em>RAD50</em>, <em>RAD51</em>, <em>RAD51B</em>, and <em>WRN</em>). Frequent HR-DDR mutations were observed in 17.4% of tumors. The overall frequency of HR-DDR mutations was 14.2% (95%CI: 13.0 to 15.5) in NSCLC (<em>n</em> = 8119), and 10.0% (95%CI: 7.4 to 13.2) in neuroendocrine/SCLC (<em>n</em> = 1498). The most mutated genes in NSCLC included <em>ARID1A</em> (4.61%), <em>ATM</em> (3.48%), <em>BRCA2</em> (0.83%), <em>CHEK2</em> (1.23%), <em>BRCA1</em> (0.83%). In SCLC, common DDR mutations were observed in <em>ARID1A</em> (4.04%), <em>ATRX</em> (2.02%), <em>ATM</em> (1.34%), <em>CHEK2</em> (1.11%) [<a href="#B27-cancers-14-05305" class="usa-link" aria-describedby="B27-cancers-14-05305">27</a>].</p>
<p>Knijnenburg et al. analyzed DDR deficiency in 33 cancer types across 9125 cancer samples from TCGA database. They performed an analysis of 276 genes, which encompassed all major DNA repair pathways: 208 genes were annotated to one or more specific DDR pathway, with an additional 68 genes being annotated to key DDR-related pathways. In LUSC genes involved in HR were altered in 16%, DRâ€”in 16%, DSâ€”in 15%, MMRâ€”12%. In LUAD, genes were altered in HRâ€”18%, DSâ€”15%, DRâ€”15% [<a href="#B10-cancers-14-05305" class="usa-link" aria-describedby="B10-cancers-14-05305">10</a>].</p>
<p>An additional study identified somatic mutations in 188 human lung adenocarcinomas with an overall mutation frequency of 14.5% for <em>ATM,</em> which is a cell-cycle checkpoint kinase [<a href="#B28-cancers-14-05305" class="usa-link" aria-describedby="B28-cancers-14-05305">28</a>]. Parry et al. systematically tested whether germline mutations in eight candidate genes could be risk factors for lung adenocarcinoma. They found 14 pathogenic mutations in five genes in 555 lung adenocarcinoma cases, with a frequency of 2.5%. Among DDR genes, <em>ATM</em> had the highest level of mutations (50%), followed by <em>BRCA2</em> (7%). This suggests that, like other solid tumors, lung adenocarcinoma has a small subset of patients with inherited susceptibility due to DDR deficiencies [<a href="#B29-cancers-14-05305" class="usa-link" aria-describedby="B29-cancers-14-05305">29</a>]. Alterations in MMR genes were identified in a subset of mostly untreated NSCLC patients (both adenocarcinoma and LUSC) that displayed low expression of the <em>MLH1</em> gene [<a href="#B30-cancers-14-05305" class="usa-link" aria-describedby="B30-cancers-14-05305">30</a>]. However, the presence of microsatellite instability is rare in both NSCLC (0.31%) and SCLC (0.61%) [<a href="#B31-cancers-14-05305" class="usa-link" aria-describedby="B31-cancers-14-05305">31</a>]. In another study, Waqar et al. identified somatic mutations in HR and Fanconi Anemia (FA) pathways in NSCLC using the cBioportal from TCGA (230 LUAD and 178 LUSC). The investigators found homozygous deletion mutation in <em>RAD51</em> (3%) in LAUD and <em>XRCC1</em> (1%) in LUSC. Other mutations that were identified included <em>BRCA1/2</em>, <em>PALB2</em>, <em>BRIP1</em>, <em>RAD51D</em>, <em>RAD54L</em> and <em>FANCA</em> [<a href="#B32-cancers-14-05305" class="usa-link" aria-describedby="B32-cancers-14-05305">32</a>]. Similarly, a patient cohort at the Dana Farber Cancer Institute, including 266 patients with advanced NSCLC who were treated with PD-(L)1 inhibitors, demonstrated the presence of pathologic DDR alterations in 49.6% of patients, with the most common mutations involving <em>ATM</em>, <em>ATR</em>, <em>BRCA2</em>, <em>POLQ,</em> and <em>RAD50</em> [<a href="#B33-cancers-14-05305" class="usa-link" aria-describedby="B33-cancers-14-05305">33</a>] (<a href="#cancers-14-05305-f002" class="usa-link">Figure 2</a>).</p>
<figure class="fig xbox font-sm" id="cancers-14-05305-f002"><h3 class="obj_head">Figure 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=9654807_cancers-14-05305-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4ac/9654807/9d59abee1842/cancers-14-05305-g002.jpg" loading="lazy" height="418" width="741" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/cancers-14-05305-f002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Reported frequencies of DDR alterations in NSCLC and SCLC. (<strong>A</strong>) Frequency of HR-DDR mutations from Caris cohort in NSCLC and SCLC represented in pie charts and, to the right of the panel, the reported frequencies of most common mutated HR-DDR genes in NSCLC (green) and SCLC (blue). (<strong>B</strong>) Selected reported frequencies in lung adenocarcinoma (LUAD) (<em>n</em> = 230) and lung squamous cell carcinoma (LUSC) (<em>n</em> = 178) from the TCGA database in NSCLC. (<strong>C</strong>) Mutation frequency in major DDR functional pathways in NSCLC from the Dana-Farber Cancer Institute cohort (<em>n</em> = 266), with blue bar charts representing frequency of the major DDR pathway mutations, and red dots representing specific highly mutated genes within the major DDR pathway. *: This cohort include metastatic non-small cell lung cancer patients treated with PD-(L)1 inhibitors.</p></figcaption></figure><p>In SCLC, key driver mutations are loss of <em>TP53</em> and <em>RB1</em> tumor-suppressor genes, which are present in approximately 80â€“90% of patients [<a href="#B34-cancers-14-05305" class="usa-link" aria-describedby="B34-cancers-14-05305">34</a>,<a href="#B35-cancers-14-05305" class="usa-link" aria-describedby="B35-cancers-14-05305">35</a>]. In addition, as outlined in the study by Heek et al., 10% of neuroendocrine/SCLC tumor samples harbor HR-DDR alterations [<a href="#B27-cancers-14-05305" class="usa-link" aria-describedby="B27-cancers-14-05305">27</a>]. A study of 166 patients with SCLC found that 47.8% had genomic alterations involving either double- or single-stranded repair genes [<a href="#B36-cancers-14-05305" class="usa-link" aria-describedby="B36-cancers-14-05305">36</a>]. Of interest, the proteomic profiling of 34 SCLC cell lines demonstrated the overexpression of DDR proteins including PARP, ATR, CHK1/2 and ATM, which was shown to provide a survival advantage for cancer cells [<a href="#B37-cancers-14-05305" class="usa-link" aria-describedby="B37-cancers-14-05305">37</a>].</p>
<p>Therefore, the presence of mutations and perhaps changes in expression in key DDR genes in lung cancer provides a rationale for further research on the biological implications of these alterations on cancer cell survival. The defective DDR pathways that lead cancer cells to rely on other compensatory DDR mechanisms could be further explored as a therapeutic target. However, more research is needed given the limited understanding of the biological consequences of DDR alterations in lung cancer.</p></section><section id="sec3-cancers-14-05305"><h2 class="pmc_sec_title">3. Prognostic and Predictive Impact of Alterations in DNA Damage Repair Genes in NSCLC</h2>
<p>Platinum therapy has long been the backbone of chemotherapy for NSCLC, although it has a historically modest survival benefit in early-stage and metastatic disease [<a href="#B38-cancers-14-05305" class="usa-link" aria-describedby="B38-cancers-14-05305">38</a>,<a href="#B39-cancers-14-05305" class="usa-link" aria-describedby="B39-cancers-14-05305">39</a>]. A 2006 study by Olaussen et al. sought to describe a validated predictor of survival benefit with an adjuvant cisplatin regimen [<a href="#B40-cancers-14-05305" class="usa-link" aria-describedby="B40-cancers-14-05305">40</a>]. As nucleoside excision repair has been understood to confer resistance to platinum-based chemotherapy, the investigators compared clinical outcomes in patients whose resected tumors had a detectable expression of ERCC1 (a critical mediator of nucleotide excision repair) to patients who did not have detected ERCC1 [<a href="#B41-cancers-14-05305" class="usa-link" aria-describedby="B41-cancers-14-05305">41</a>,<a href="#B42-cancers-14-05305" class="usa-link" aria-describedby="B42-cancers-14-05305">42</a>]. The authors found that patients with ERCC1+ tumors did not derive any significant survival benefit from adjuvant cisplatin compared to the control arm, which suggested a predictive role of ERCC1 status to cisplatin sensitivity [<a href="#B40-cancers-14-05305" class="usa-link" aria-describedby="B40-cancers-14-05305">40</a>]. While these results were encouraging, subsequent analyses raised the concern that the available antibodies could not always reliably select for the functional ERCC1 isoform, thus limiting their utility as a predictive tool in the clinical setting [<a href="#B43-cancers-14-05305" class="usa-link" aria-describedby="B43-cancers-14-05305">43</a>,<a href="#B44-cancers-14-05305" class="usa-link" aria-describedby="B44-cancers-14-05305">44</a>]. This study has provided a proof-of-concept on the possible role of DDR pathway alterations as a possible predictor of response to lung cancer treatment.</p>
<p>The role of other DDR pathway alterations in predicting NSCLC response to platinum therapy has also been assessed. Despite the association between <em>BRCA</em> mutations with platinum sensitivity in other tumor types, alterations in <em>BRCA</em> remain controversial regarding their predictive ability in NSCLC treated with platinum-based therapy [<a href="#B45-cancers-14-05305" class="usa-link" aria-describedby="B45-cancers-14-05305">45</a>,<a href="#B46-cancers-14-05305" class="usa-link" aria-describedby="B46-cancers-14-05305">46</a>,<a href="#B47-cancers-14-05305" class="usa-link" aria-describedby="B47-cancers-14-05305">47</a>]. For example, a retrospective study of tumor specimens from 100 NSCLC patients treated with platinum-based therapy assessed the effect of low BRCA1 expression on response and survival. The authors found that the low expression of <em>BRCA1</em> detected by RT-qPCR was associated with higher response rates and longer progression-free survival (PFS) and OS [<a href="#B48-cancers-14-05305" class="usa-link" aria-describedby="B48-cancers-14-05305">48</a>]. However, this study did not investigate <em>BRCA1</em> alterations on the genomic or epigenomic levels. In contrast, Wang et al. analyzed BRCA1 expression in 418 patients who underwent surgical resection of NSCLC, followed by platinum-based therapy, and found no significant association between BRCA1 expression and response to treatment or survival [<a href="#B49-cancers-14-05305" class="usa-link" aria-describedby="B49-cancers-14-05305">49</a>]. In another subset of NSCLC, an in vitro analysis of cisplatin-resistant KRAS<sup>G12C</sup> expressing tumors found an increased level of base excision repair proteins, which was hypothesized to confer resistance to cisplatin through the rapid removal of platinum-DNA adducts prior to crosslinking [<a href="#B50-cancers-14-05305" class="usa-link" aria-describedby="B50-cancers-14-05305">50</a>]. Moreover, an analysis of individual polymorphisms of four genes in lung tumors within the base excision repair pathway found that those that reduced DNA damage repair were associated with greater response to platinum-based chemotherapy [<a href="#B51-cancers-14-05305" class="usa-link" aria-describedby="B51-cancers-14-05305">51</a>]. Regarding genomic DDR alterations, Dai et al. found no predictive role of DDR deleterious alterations and survival in NSCLC treated with chemotherapy [<a href="#B52-cancers-14-05305" class="usa-link" aria-describedby="B52-cancers-14-05305">52</a>]. Patients who had alterations in base excision repair and nucleotide excision repair pathways had worse PFS in LUAD and LUSC, respectively. Conversely, another group found an association between shorter OS and PFS in patients with homologous recombination pathway alterations who had LUSC and were treated with carboplatin and nab-paclitaxel [<a href="#B53-cancers-14-05305" class="usa-link" aria-describedby="B53-cancers-14-05305">53</a>]. Therefore, the clinical utility of DDR alterations or protein expression to predict chemosensitivity and survival has not been supported in the literature to date.</p>
<p>Mechanisms of NSCLC radioresistance have recently been elucidated, implicating DDR pathway activation. Several pre-clinical studies utilizing siRNA knockdown techniques have identified important mediators. <em>RAD50</em>, a gene-encoding double-strand break-repair protein, was found to confer resistance to radiotherapy in a model of NSCLC [<a href="#B54-cancers-14-05305" class="usa-link" aria-describedby="B54-cancers-14-05305">54</a>]. The authors demonstrated that RAD50 over-expression was correlated with shorter disease-free survival and radioresistance in lung cancer patients who underwent tumor resection followed by post-operative radiation therapy [<a href="#B54-cancers-14-05305" class="usa-link" aria-describedby="B54-cancers-14-05305">54</a>]. Additionally, DNA damage binding protein 2 (DDB2) was shown to promote resistance through its role in DDR enhancement of the HR pathway, as well as playing a role in NER [<a href="#B55-cancers-14-05305" class="usa-link" aria-describedby="B55-cancers-14-05305">55</a>,<a href="#B56-cancers-14-05305" class="usa-link" aria-describedby="B56-cancers-14-05305">56</a>].</p>
<p>The advent of the immune checkpoint blockade represented a major advancement in the treatment of NSCLC. The search for predictive biomarkers for immunotherapy response is ongoing, as only a subset of cancer patients show objective responses with durable remission. Given the association between neoantigen expression and response to immunotherapy, it has been proposed that mutations in DDR pathways could be associated with improved ICI outcomes [<a href="#B57-cancers-14-05305" class="usa-link" aria-describedby="B57-cancers-14-05305">57</a>]. Recent studies show an association between mutation in several DDR pathways (including homologous recombination, base excision repair, nucleotide excision repair, and non-homologous end joining) and increased tumor mutational burden (TMB) in NSCLC [<a href="#B52-cancers-14-05305" class="usa-link" aria-describedby="B52-cancers-14-05305">52</a>,<a href="#B58-cancers-14-05305" class="usa-link" aria-describedby="B58-cancers-14-05305">58</a>,<a href="#B59-cancers-14-05305" class="usa-link" aria-describedby="B59-cancers-14-05305">59</a>]. Ricciuiti et al., demonstrated that pathogenic DDR mutations (shown in <a href="#cancers-14-05305-f002" class="usa-link">Figure 2</a>, Panel C) were associated with improved response rate, PFS, and OS in NSCLC patients treated with PD-(L)1 inhibitors as a monotherapy or in combination with a CTLA-4 inhibitor [<a href="#B33-cancers-14-05305" class="usa-link" aria-describedby="B33-cancers-14-05305">33</a>]. Among 266 patients, those who had deleterious alterations in DDR genes had higher objective response rates (ORR) of 30.3% versus 17.2% in patients without identified pathogenic DDR mutations (<em>p</em> = 0.01). The median PFS and OS were longer in DDR-altered patients compared to patients without DDR alterations (median PFS 5.4 vs. 2.2 months, median OS 18.8 vs. 9.9 months, respectively, and both statistically significant). The survival benefit was also replicated when adjusting for TMB and PD-L1 expression. However, the predictive role of DDR alterations was incompletely answered in this study regarding patients who received chemoimmunotherapy, as those patients were not included in the study. Similarly, another study demonstrated that the presence of co-mutations in the DDR pathway (including <em>TP53</em>) served as a predictor of response to atezolizumab in NSCLC, even in patients with negative or low PDL-1 expression [<a href="#B60-cancers-14-05305" class="usa-link" aria-describedby="B60-cancers-14-05305">60</a>]. The authors defined co-mutation as the presence of DDR alterations in two or more DDR pathways (including 29 DDR genes from HR, MMR, BER, NER and NHEJ).</p>
<p>Finally, the study of the role of HRD score as a biomarker of response to different therapeutics in NSCLC is still under investigation. Doissy et al. demonstrated an exceptional duration of response of more than 20 months in a LUSC patient who received platinum-based therapy and had a high HRD score which ranked amongst the highest of 489 lung cancer cases in the GDC data portal. Moreover, the authors suggested that a high HRD score (&gt;0.70), using HRDetect assay, was predictive of lung cancer cell line sensitivity to olaparib and talazoparib, suggesting a possible role of PARP inhibitors in a select population [<a href="#B46-cancers-14-05305" class="usa-link" aria-describedby="B46-cancers-14-05305">46</a>].</p>
<p>The results of these retrospective studies suggest that DDR alterations are not useful as predictive biomarkers for chemosensitivity but may have a role in predicting radio-resistance and response to immunotherapy in lung cancer. The integration of such biomarkers in the clinical setting (especially in the case of DDR alterations and immunotherapy) will depend on further validation in large prospective cohorts in NSCLC patients.</p></section><section id="sec4-cancers-14-05305"><h2 class="pmc_sec_title">4. The Clinical Relevance of Targeting HR Pathway in Patients with HRD in NSCLC</h2>
<p>Most of the data on the clinical efficacy of targeting HRD cancers come from PARPi trials in ovarian, breast, prostate, and pancreatic cancers. These tumors harbor HR deficiencies either due to <em>BRCA1/2</em> mutations or other HR-DDR alterations that render malignant cells susceptible to the inhibition of both BER and NHEJ pathways by trapping the PARP1 enzyme. Several PARPi have been approved by the FDA and EMA including olaparib, talazoparib, niraparib, and rucaparib. Initial preclinical studies showed that <em>BRCA-2-</em>deficient cell lines were sensitive to PARP inhibitors, human breast cancer cell lines, and tumor xenografts. Both PARP-1 and PARP-2 were inhibited; however, the reversal of the homologous recombination activity eliminated sensitivity [<a href="#B61-cancers-14-05305" class="usa-link" aria-describedby="B61-cancers-14-05305">61</a>]. In another key preclinical study, the combination of AZD2281 (olaparib, LYNPARZAâ„¢, AstraZeneca) and a platinum drug (cisplatin or carboplatin) in a genetically engineered mouse model with mammary tumors demonstrated improved recurrence-free survival and OS [<a href="#B62-cancers-14-05305" class="usa-link" aria-describedby="B62-cancers-14-05305">62</a>]. In vitro, olaparib-induced cytotoxicity has been shown to involve a reduction in PARP enzymatic activity and enhanced formation of the PARP-DNA complex, resulting in cell homeostasis disruption and cell death in NCI-60 cell lines [<a href="#B63-cancers-14-05305" class="usa-link" aria-describedby="B63-cancers-14-05305">63</a>]. Several phase-3 randomized controlled trials demonstrated improved PFS and OS using different PARPi in <em>BRCA1/2</em> mutated breast and ovarian cancers. Interestingly, the benefit was also noted in some wild-type <em>BRCA</em> tumors, which was later shown to be mediated by other deleterious deficiencies in DDR pathway, leading to an HRD state. This was demonstrated in a phase-3 randomized trial (PAOLA1) for the maintenance of olaparib and bevacizumab in a first-line setting in HRD-positive ovarian cancer, which improved PFS, and another randomized phase-3 trial in metastatic castration-resistant prostate cancer with alterations in HR genes (PROfound study), which demonstrated improved PFS [<a href="#B64-cancers-14-05305" class="usa-link" aria-describedby="B64-cancers-14-05305">64</a>,<a href="#B65-cancers-14-05305" class="usa-link" aria-describedby="B65-cancers-14-05305">65</a>]. These encouraging results led to several efforts to test the efficacy of these medications in other tumor types, including lung cancer.</p>
<p>Several trials have been conducted on the efficacy of PARPi in NSCLC given their sensitivity to platinum-based regimens, which is a predictive factor for response to PARP inhibition [<a href="#B66-cancers-14-05305" class="usa-link" aria-describedby="B66-cancers-14-05305">66</a>,<a href="#B67-cancers-14-05305" class="usa-link" aria-describedby="B67-cancers-14-05305">67</a>]. However, these trials did not demonstrate improved outcomes with the use of PARPi. The PIN trial, a phase-2 randomized-control trial, assigned 70 platinum-sensitive NSCLC patients, irrespective of BRCA mutation status, to either olaparib or placebo. Patients receiving olaparib had a notably longer, though not statistically significant, PFS (16.6 months as compared to 12 months, HR 0.83, 80% CI 0.6â€“1.15, <em>p</em> = 0.23). Of note, these patients were not required to have documented DDR pathway mutations [<a href="#B68-cancers-14-05305" class="usa-link" aria-describedby="B68-cancers-14-05305">68</a>]. S1900A, a phase-2 Lung-MAP sub-study, investigated whether NSCLC patients with demonstrated HRD had improved outcomes with rucaparib. They enrolled NSCLC patients with a documented high genomic loss of heterozygosity (LOH) or known <em>BRCA1/2</em> mutations who had disease progression on standard platinum-based or anti-PD-(L)1 therapy. The study was closed after interim analysis demonstrated futility with insufficient responses, however, 3 out of 4 total responders to rucaparib demonstrated <em>BRCA1</em> or <em>BRCA2</em> mutations [<a href="#B69-cancers-14-05305" class="usa-link" aria-describedby="B69-cancers-14-05305">69</a>]. This suggests that NSCLC patients with <em>BRCA1/2</em> mutations may have non-BRCA related alterations, leading to patientsâ€™ benefitting from the addition of PARPi therapy. Further supporting this, a 26-year-old woman with stage 4 adenocarcinoma found to have a germline mutation in <em>BRCA2 (S497*)</em> without other targetable mutations had an excellent clinical response to combination pembrolizumab and olaparib [<a href="#B70-cancers-14-05305" class="usa-link" aria-describedby="B70-cancers-14-05305">70</a>]. Importantly, preclinical data have offered evidence that olaparib upregulates PD-L1 expression, suggesting potential therapeutic synergy with checkpoint blockade [<a href="#B71-cancers-14-05305" class="usa-link" aria-describedby="B71-cancers-14-05305">71</a>]. Currently, the KEYLYNK-006 study (<a href="https://clinicaltrials.gov/ct2/show/NCT03976323" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03976323</a>) is investigating the efficacy of the combination pembrolizumab with maintenance olaparib vs. maintenance pemetrexed in non-squamous NSCLC; however, patients are not required to have mutations in the DDR pathway.</p>
<p>Discoveries of targetable driver mutations have led to a significant improvement in the prognosis and treatment of NSCLC. However, this has largely only benefited patients with adenocarcinoma, a histologic subset of NSCLC. Squamous cell Carcinoma (LUSC), which represents approximately 30% of all NSCLC, has not had the same success in the identification and development of targeted therapies for driver mutations [<a href="#B72-cancers-14-05305" class="usa-link" aria-describedby="B72-cancers-14-05305">72</a>]. Given the high rate of high tumor mutation burdens in LUSC, several studies have been conducted to address the role of PARPi in these tumors. S1400AG, a Lung-MAP sub-study, evaluated the efficacy of PARPi talazoparib in HRD-LUSC [<a href="#B73-cancers-14-05305" class="usa-link" aria-describedby="B73-cancers-14-05305">73</a>]. The primary analysis population were required to have mutations in the following genes: <em>ATM, ATR, BRCA1, BRCA2,</em> and <em>PALB2</em>; however, the full eligible population of the study included mutations in additional HR pathway genes, including the Fanconi Anemia (FA) repair pathway. A total of 47 patients were enrolled, with 24 included in the primary analysis population. Overall, the study failed to demonstrate the efficacy of talazoparib. Interestingly however, 4 of 5 patients with objective response had alterations in the <em>FANCM</em>, <em>FANCC</em>, or <em>CHEK1</em> genes, which were not included in the primary analysis population. Therefore, further investigation into the potential therapeutic benefit of using PARPi in LUSC patients with FA repair pathway mutations may be warranted.</p>
<p>A recent large phase-3 randomized multicenter trial compared the use of veliparib in addition to platinum-based chemotherapy in patients with advanced squamous cell lung cancer in the first-line setting versus the use of chemotherapy alone. The rational of PARPi use in the first-line setting was due to the fact that DNA damage plays an important role in LUSC and due to preclinical studies demonstrating the efficacy of PARPi in LUSC with deficient DDR [<a href="#B74-cancers-14-05305" class="usa-link" aria-describedby="B74-cancers-14-05305">74</a>,<a href="#B75-cancers-14-05305" class="usa-link" aria-describedby="B75-cancers-14-05305">75</a>], and prior clinical evidence from a prior randomized phase-2 trial showing the benefits of PARP inhibition in squamous NSCLC [<a href="#B76-cancers-14-05305" class="usa-link" aria-describedby="B76-cancers-14-05305">76</a>]. The confirmatory phase 3 trial failed to demonstrate improved OS with the addition of veliparib with comparable safety [<a href="#B77-cancers-14-05305" class="usa-link" aria-describedby="B77-cancers-14-05305">77</a>]. Authors performed correlative biomarker analysis of the impact of binary gene-expression tumor-profiling measured by qRT-PCR (referred to as LP52) [<a href="#B78-cancers-14-05305" class="usa-link" aria-describedby="B78-cancers-14-05305">78</a>]. The authors studied the molecular features of squamous cell lung cancer and, based on gene expression, was classified as LP52-positive (molecular expression consistent with non-adenocarcinoma histology) and LP52-negative (adenocarcinoma molecular features). The authors found that LP52-positive patients had improved OS with the addition of veliparib and LP52-negative patients had a better outcome with chemotherapy alone (14 months vs. 6 months), suggesting that selected patient populations may benefit from the addition of PARPi; however, DDR alterations were not included in gene expression profiling. Another phase-3 randomized clinical trial in advanced non-squamous NSCLC failed to demonstrate a benefit of adding veliparib to chemotherapy backbone in first-line treatment, although OS was numerically higher (11.2 months vs. 9.2 months, respectively, <em>p</em> = 0.113) [<a href="#B79-cancers-14-05305" class="usa-link" aria-describedby="B79-cancers-14-05305">79</a>].</p>
<p>Despite the lack of efficacy of PARPi with chemotherapy in several lung cancer trials, there is an ongoing effort to investigate the possible role of combining PARPi with immunotherapy in NSCLC due to the synergistic effect of the combination treatment and acceptable safety [<a href="#B80-cancers-14-05305" class="usa-link" aria-describedby="B80-cancers-14-05305">80</a>,<a href="#B81-cancers-14-05305" class="usa-link" aria-describedby="B81-cancers-14-05305">81</a>]. The GUIDE2REPAIR trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04169841" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04169841</a>) is an ongoing, Phase-2, non-randomized study, which seeks to assess the safety and efficacy of combination olaparib, durvalumab and tremelimumab in patients with metastatic solid-tumor malignancy, including NSCLC, and the identified mutations in HR pathway genes [<a href="#B82-cancers-14-05305" class="usa-link" aria-describedby="B82-cancers-14-05305">82</a>]. The UNITO-001 (<a href="https://clinicaltrials.gov/ct2/show/NCT04940637" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04940637</a>) is another prospective, single-arm, phase-2 trial investigating the safety and efficacy of combination niraparib and dostarlimab in patients with advanced NSCLC and malignant pleural mesothelioma with germline or somatic mutations in HR genes and positive PD-L1 expression (TPS â‰¥ 1%). At present, they are actively enrolling patients, and have an estimated completion date of January 2024 [<a href="#B83-cancers-14-05305" class="usa-link" aria-describedby="B83-cancers-14-05305">83</a>]. <a href="#cancers-14-05305-t001" class="usa-link">Table 1</a> summarizes the current PARPi that are in clinical trials in NSCLC [<a href="#B84-cancers-14-05305" class="usa-link" aria-describedby="B84-cancers-14-05305">84</a>,<a href="#B85-cancers-14-05305" class="usa-link" aria-describedby="B85-cancers-14-05305">85</a>,<a href="#B86-cancers-14-05305" class="usa-link" aria-describedby="B86-cancers-14-05305">86</a>,<a href="#B87-cancers-14-05305" class="usa-link" aria-describedby="B87-cancers-14-05305">87</a>]. Recently, Marzio et al. demonstrated the role of Klech-like ECH-associated protein 1 (<em>KEAP1)</em> mutation, which is an important redox hemostasis regulator, in producing BRCAness phenotype in NSCLC [<a href="#B88-cancers-14-05305" class="usa-link" aria-describedby="B88-cancers-14-05305">88</a>]. The investigators demonstrated that KEAP1 knockout led to the stabilization of EMSY, an important inhibitor of BRCA2, which led to a homologuesâ€™ recombination-deficient state. In addition, accumulation of EMSY was associated with type I interferon suppression, which, in turn, promoted immune escape. The administration of PARP inhibitors had anti-tumor efficacy in KEAP1 mutant NSCLC and this was further augmented with the addition of STING agonist, providing a rationale for the use of PARP inhibitors in NSCLC with BRCAness phenotype due to the KEAP1 mutation.</p>
<section class="tw xbox font-sm" id="cancers-14-05305-t001"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>A summary of selected clinical trials with PARPi in NSCLC.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Medication</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tumor Type</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inclusion Criteria</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Exclusion Criteria</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Selective Biomarkers</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">End Point</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01513174" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01513174</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Olaparib + Gefitinb vs. Gefitinib alone <br>Phase 1 and Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4 disease <br>ECOG score â‰¤ 2.<br>Life expectancy of â‰¥ 3 months.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior treatment with PARPi<br>History of ILD<br>2nd neoplasm</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR+</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Maximum tolerated dose<br>Secondary: PFS, ORR, OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPFS 12.8 vs. 10.9 (<em>p</em> = 0.124)<br>mOS 23.3 vs. 23.1 (<em>p</em> = 0.345)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B84-cancers-14-05305" class="usa-link" aria-describedby="B84-cancers-14-05305">84</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01562210" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01562210</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Olaparib dose escalating + RT with or without cisplatin <br>Phase 1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 2/3 non-operable disease <br>Life expectancy of â‰¥ 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior radiation/chemotherapy<br>Significant pulmonary, cardiovascular, hepatic disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targetable mutations</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>dose-limiting toxicity<br>Secondary:<br>PFS, ORR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose limiting toxicity due to esophageal, hematologic and pulmonary toxicity</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B85-cancers-14-05305" class="usa-link" aria-describedby="B85-cancers-14-05305">85</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03775486" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03775486</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Durvalumab + Olaparib vs Durvalumab<br>Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4 NSCLC, not amenable to curative surgery or radiation</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of autoimmune disease<br>Prior chemo/immune therapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR mutation negative ALK fusions negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>PFS<br>Secondary:<br>OS, ORR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03976362" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03976362</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab +/- maintenance Olaparib<br>Phase 3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">squamous<br>NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4, life expectancy â‰¥ 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of autoimmune disease <br>History of ILD</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>PFS, OS <br>Secondary:<br>AE, QLQ-C30</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04380636" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04380636</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab with chemoradiation, followed by pembrolizumab +/âˆ’ Olaparib <br>Phase 3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3, unresectable, life expectancy â‰¥ 6 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior treatment <br>History of autoimmune disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>PFS, OS <br>Secondary:<br>AE, ORR, DOR, QLQ-C30</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03976323" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03976323</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab followed by maintenance Olaparib vs. pemetrexed <br>Phase 3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-squamous<br>NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4, life expectancy â‰¥ 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of autoimmune disease<br>Prior therapy with PARPi<br>CNS disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR, ROS1 mutations negative, ALK fusions negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>PFS, OS <br>Secondary:<br>AE, ORR, QLQ-C30</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03334617" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03334617</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Umbrella study of novel agents (Olaparib) +Durvalumab <br>Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4, progressed on anti PD1/PD-L1, life expectancy â‰¥ 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">History of primary immunodeficiency or autoimmune disorders, CNS disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR mutation negative ALK fusions negative<br>ROS1, BRAF, MET, RET negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>ORR<br>Secondary:<br>DCR, DOR, PFS, OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04550104" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04550104</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platform study of novel agents (olaparib) with radiotherapy <br>Phase 1B</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 2B/3A/3B, not eligible for concurrent chemoradiotherapy/surgery <br>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior autoimmune or inflammatory disorders, history of interstitial pneumonitis</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>Dose-limiting toxicities <br>Secondary:<br>ORR, OS, PFS, QLQ-C30</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03559049" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03559049</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rucaparib and Pembrolizumab for maintenance therapy <br>Phase 1/2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-squamous NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4, life expectancy â‰¥ 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior systemic therapy, prior treatment with PARPi, history of autoimmune disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR mutation negative ALK fusions negative<br>ROS1 negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>PFS<br>Secondary:<br>OS, ORR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03845296" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03845296</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rucaparib (LUNG-MAP Sub-Study) <br>Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior treatment with PARPi, Grade 3/4 CV disease,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genomic LOH or BRCA 1, 2 mutations <br>ALK fusions negative<br>EGFR, ROS1, BRAF mutations negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary:<br>ORR<br>Secondary:<br>IA-PFS, OS, DOS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03891615" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03891615</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1â€”Niraparib with combination osimertinib in EGFR mutated lung cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4, EGFR mutant NSCLC, life expectancy &gt; 6 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No prior PARP inhibitor, prior immunotherapy, ILD,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Max tolerated dose<br>Secondary: Rate of toxicity in combined, ORR niraparib, median PFS niraparid</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03497429" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03497429</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1 niraparib in Japanese pts w/advanced solid tumors</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adv Solid tumor</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Met or locally advanced solid tumor malignancy,<br>Japanese, &gt;20 years old</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior PARPi, CNS mets,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Dose-limiting toxicity<br>Secondary: Plasma concentration, AUC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT05169437" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05169437</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2 niraparib in locally advanced on met PALB2 mutations</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adv Solid Tumor</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Met or locally advanced, Pathogenic PALB2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian or prostate ca, prior ParpI therapy, BRCA1 or 2,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathogenic PALB2 +, BRCA 1 and BRCA 2 negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: ORR<br>Secondary: PFS, ORR, AE events, OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04475939" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04475939</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ZEAL-1Lâ€”Phase 3 RCT, Niraparib + pembro vs. Placebo + pembro in NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Met or locally advanced, life expectancy &gt; 12 wks</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior ParpI, brain mets, autoimmune disorder,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: PFS, OS<br>Secondary: TTP, PFS by PDL1 status, IRAEs</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Results from phase 2 trial: ORR 56.3% with TPS â‰¥ 50 (Cohort 1) and 20% in TPS 1â€“49% (Cohort 2).<br>mPFS: 8.4 in cohort 1 and 4.2 in cohort 2.<br>mOS NR in cohort 1 and 7.7 in cohort 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B86-cancers-14-05305" class="usa-link" aria-describedby="B86-cancers-14-05305">86</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03308942" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03308942</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2 niraparib + anti -PD-1 (Pembro vs. Dostarlimab)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC (cohort 3â€”sqaumous)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Met or locally advanced, Cohort 1â€”PDL-1 &gt; 50% cohort 2- PDL-1 1â€“49%; Cohort 3â€”SqCC,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort 1/2; Prior Anti-PD1, PDL-1 or PDl-2 therapy<br>All cohorts- hx of immunodeficiency, hx of autoimmune disease, ILD or pneumonitis</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ROS-, ALK-, EGFR-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: ORR<br>Secondary: Non-SAEs, SAEs, duration of response, PFS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03209401" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03209401</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1â€”Niraparib + carboplatin in HRR deficient adv solid tumors</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adv solid tumor</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Life expectancy &gt; 3 mo,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior platinum chemotherapy w/in last 6 mo. Prior PARPi, CNS disease,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HR pathway mutations</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: Grade 3â€“4 toxicities, ORR<br>Secondary: Median survival, PFS, DCR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02944396" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02944396</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib in combination with Nivolumab and Platinum doublet <br>Phase 1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4 or unresectable Stage 3B <br>Life expectancy &gt; 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior therapy with PARPi or checkpoint inhibitor <br>CNS disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>PFS, RPTD <br>Secondary: OS, AUC, DOR, Cmax</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT02264990" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02264990</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib + carboplatin and paclitaxel v investigatorâ€™s choice chemotherapy <br>Phase 3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-squamous NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3 unresectable, stage 4<br>Current or former smoker</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peripheral neuropathy, Prior cytotoxic chemo or radiation for NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR mutation negative<br>ALK fusion negative <br>LP52+</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>Number of participants with DLT<br>Secondary: ORR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mOS 12.1 in both arms (<em>p</em> = 0.846)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B79-cancers-14-05305" class="usa-link" aria-describedby="B79-cancers-14-05305">79</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01560104" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01560104</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib vs. placebo in combination with carboplatin and paclitaxel<br>Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3 unresectable, stage 4<br>Life expectancy &gt; 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peripheral neuropathy, Prior cytotoxic chemo or radiation for NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR mutation negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>PFS<br>Secondary: <br>OS, ORR, CIPN</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mPFS 5.8 months vs. 4.2 months (<em>p</em> = 0.17).<br>mOS 11.7 vs. 9.1 (<em>p</em> = 0.27).<br>ORR: 32.4% vs. 32.1%</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B76-cancers-14-05305" class="usa-link" aria-describedby="B76-cancers-14-05305">76</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT012106546</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib vs. placebo in combination with carboplatin and paclitaxel <br>Phase 3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Squamous NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3 unresectable, stage 4<br>Life expectancy &gt; 3 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peripheral neuropathy, Prior cytotoxic chemo or radiation for NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR mutation negative<br>ALK fusion negative</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>OS (current smokers) <br>Secondary: <br>OS (all subjects), PFS, ORR</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mOS 11.9 months vs. 11.1 months (<em>p</em> = 0.266).</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B77-cancers-14-05305" class="usa-link" aria-describedby="B77-cancers-14-05305">77</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01657799" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01657799</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib 50 BID with WBRT vs. veliparib 200 BID with WBRT vs. placebo with WBRT for NSCLC Brain metastases Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain mets on MRI, eligible for WBRT, adequate hematologic, renal, and hepatic function</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dx of brain mets &gt; 28 days prior to day 1, more than 2 sites of metastasis, leptomeningeal spread, prior PARPi therapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>OS <br>Secondary: <br>Best tumor response rate, time to intracranial progression</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mOS 209 days vs. 209 days vs 185 days <em>p</em> &gt;0.05</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B87-cancers-14-05305" class="usa-link" aria-describedby="B87-cancers-14-05305">87</a>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01386385" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01386385</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib with or without radiation, carboplatin, and paclitaxel <br>Phase 1 followed by Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3 unresectable disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior cytotoxic chemo or radiation for NSCLC<br>Immune disorder</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>Maximum tolerated dose, <br>PFS<br>Secondary: <br>OS, ORR, incidence of Grade 3+ AE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT01282333" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01282333</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Veliparib, cisplatin, and gemcitabine hydrochloride <br>Phase 1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC, (+biliary, pancreatic, urothelial cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3 unresectable, Stage 4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior cytotoxic chemo or radiation</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA1 or BRCA 2 germline mutation</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>Maximum tolerated dose<br>Secondary: <br>Dose-limiting toxicities, antitumor activity</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A <br>(terminated)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT04173507" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04173507</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Talazoparib plus avelumab <br>(LUNG-MAP trial) <br>Phase 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 4 or recurrent disease <br>Prior treatment with one line of anti-PD-1 or PD-L1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior PARPi, Grade 2/4 cardiac disease,</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STK11 gene mutation</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>ORR<br>Disease control rate<br>Secondary: <br>Toxicities, PFS, OS, Duration of response</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><a href="https://clinicaltrials.gov/ct2/show/NCT03330405" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03330405</a></td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avelumab plus Talazoparib <br>Phase 1/2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC, Ovarian, urothelial, TNBC</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage 3 unresectable, Stage 4, ECOG 1, 2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prior PARPi, history of brain mets requiring steroid, autoimmune disease</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA, ATM mutations</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary: <br>DLT, OR<br>Secondary: <br>TTR, DOR, PFS, OS</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trial</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/cancers-14-05305-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p>Abbreviations: NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; ILD: interstitial lung disease; RT: radiation therapy; PFS: progression-free survival; OS: overall survival; N/A: not available; AE: adverse events; QLQ-C3-: Quality of Life Questionnaire-Core 30; ORR: objective response rate; DOR: duration of response; DCR: disease control rate; IA-PFS: investigator assessed progression-free survival; LOH: loss of heterozygosity; HR: homologous recombination; TTP: treatment to progression; IRAEs: immune-related adverse events; SAE: serious adverse events; AUC: area under curve; RPTD: recommended phase-2 dose; WBRT: whole-brain radiation therapy; TTR: time to tumor response.</p></div></div></section><p>Beyond PARP inhibition, most of the other novel DDR inhibitors are currently being studied in early-phase clinical trials in solid tumors. Preclinical evidence suggests that the inhibition of ATR in NSCLC cell lines increases sensitivity to both cisplatin and radiation therapy [<a href="#B89-cancers-14-05305" class="usa-link" aria-describedby="B89-cancers-14-05305">89</a>,<a href="#B90-cancers-14-05305" class="usa-link" aria-describedby="B90-cancers-14-05305">90</a>]. A phase 1b/2 trial is underway to evaluate the safety and efficacy of adding an ATR inhibitor berzosertib (M6620 VX-970) to chemotherapy and immunotherapy in metastatic squamous NSCLC (<a href="https://clinicaltrials.gov/ct2/show/NCT04216316" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04216316</a>). Another phase 1 trial is evaluating the safety of the addition of berzosertib to whole-brain radiation for the treatment of brain metastases of SCLC and NSCLC (<a href="https://clinicaltrials.gov/ct2/show/NCT02589522" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02589522</a>). Another ATR inhibitor, ceralasertib (AZD6738), is currently being evaluated in a phase 2 umbrella trial in NSCLC (the HUDSON trial) in patients who progressed on anti-PD-(L)1 therapy (<a href="https://clinicaltrials.gov/ct2/show/NCT03334617" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03334617</a>). AZD6738, which is an ATM/ATR inhibitor, has demonstrated acceptable safety in phase 1 clinical trials in solid tumors when combined with carboplatin, with olaparib or with durvalumab [<a href="#B91-cancers-14-05305" class="usa-link" aria-describedby="B91-cancers-14-05305">91</a>]. Similarly, other inhibitors of DDR proteins, such as ATM, CHEK1/2, WEE1 and DNA-PK, are currently being evaluated in early-phase clinical trials in solid tumors including NSCLC, and are summarized in <a href="#app1-cancers-14-05305" class="usa-link">Supplementary Table S1</a>.</p>
<p>In summary, PARP inhibitors did not demonstrate clinical efficacy in NSCLC despite the notion that platinum-sensitive cancers could be responsive to PARPi. Further studies are needed to analyze the efficacy of PARPi in the subset of patients with specific DDR alterations that could lead to <em>BRCA</em> deficiency or an HRD phenotype. This will require further understanding of the biological implications of specific DDR alterations on cancer cell dependence on compensatory repair pathways. The development of validated HRD assays specific to lung cancer could be of interest regarding whether they could select for a biologically distinct tumor subtype that could be more sensitive to DDR targeting the containing regimen. Furthermore, the combination of PARPi with checkpoint inhibitors is of interest, given the preclinical evidence of synergism and relative safety compared to combining PARPi with chemotherapy.</p></section><section id="sec5-cancers-14-05305"><h2 class="pmc_sec_title">5. Prognostic and Predictive Biomarkers in DNA Damage Pathway Alterations in SCLC</h2>
<p>Tumor-suppressor genes of retinoblastoma protein (RB) and the p53 transcription factor are one of the most commonly mutated genes across all cancer types. SCLC harbors <em>RB</em> loss-of-function alterations in approximately 80% of cases, and <em>TP53</em> is mutated in the majority of SCLC [<a href="#B92-cancers-14-05305" class="usa-link" aria-describedby="B92-cancers-14-05305">92</a>]. Alterations in the DDR genes are infrequently present in SCLC (with the exception of <em>TP53</em>), as discussed in <a href="#sec2-cancers-14-05305" class="usa-link">Section 2</a>. However, the overexpression of several DDR-related proteins, such as PARP1, has been linked to the pathogenesis and response to treatment. In SCLC, cell line showed the highest PARP1 expression of any solid tumor line, including breast and ovarian cells, among individual cell lines [<a href="#B37-cancers-14-05305" class="usa-link" aria-describedby="B37-cancers-14-05305">37</a>]. <em>PARP1</em> and <em>EZH2</em> gene knockdowns decreased SCLC growth. When compared to NSCLC, SCLC is much more responsive to PARP inhibitors, and PARP inhibition downregulated critical components of the DNA repair mechanism while improving chemotherapy effectiveness in SCLC [<a href="#B37-cancers-14-05305" class="usa-link" aria-describedby="B37-cancers-14-05305">37</a>].</p>
<p>There have been several attempts to use HRD assays as a predictive tool of response to PARPi in SCLC. Those assays, based on an analysis of preexisting genomic mutations, did not show correlations with SCLC sensitivity to PARP inhibition. However, it was found that schlafen family member 11 (SLFN11) correlated with PARPi sensitivity and could be used through CRISPR/Cas9 and shRNA approaches to knock out SLFN11 [<a href="#B93-cancers-14-05305" class="usa-link" aria-describedby="B93-cancers-14-05305">93</a>]. Several studies showed different SLFN11 results as a predictive marker, as some studies supported that high expression of SLFN11 correlated with response to PARP inhibitors. In the Lok et al. study, it was shown that SLFN11 was a relevant predictive biomarker of susceptibility to PARP inhibitor monotherapy in SCLC. Combination treatment with temozolomide (TMZ) stood out as a particularly interesting therapeutic strategy. Patients with SLFN11-positive tumors treated with TMZ and veliparib showed prolonged PFS (5.7 vs. 3.6 months; <em>p</em> = 0.009) and OS (12.2 vs. 7.5 months; <em>p</em> = 0.014) [<a href="#B93-cancers-14-05305" class="usa-link" aria-describedby="B93-cancers-14-05305">93</a>]. Similarly, Pietanza et al. found a considerable improvement in ORR with TMZ and veliparib in patients receiving this combination, where SLFN11 expression in tumors was related to better PFS and OS, indicating a predictive biomarker of PARP-inhibitor sensitivity in SCLC [<a href="#B94-cancers-14-05305" class="usa-link" aria-describedby="B94-cancers-14-05305">94</a>]. Murai et al. investigated SLFN11 as a potentially relevant biomarker of response for patients treated with PARPi, as well as for combining ATR and PARP inhibitors to overcome SLFN11-negative cellsâ€™ resistance to PARPi. They identified SLFN11 as a causative and dominating predictor of cellular responsiveness to PARPi (talazoparib and olaparib), both alone and in combination with TMZ. The study showed that SLFN11 affects cellular responses to PARPi independently of homologous recombination and drug efflux by inhibiting DNA replication without the involvement of ATR [<a href="#B63-cancers-14-05305" class="usa-link" aria-describedby="B63-cancers-14-05305">63</a>]. Gay et al. defined four subgroups of SCLC, each with distinct molecular characteristics and treatment vulnerabilities. The clinical implications of this subtype categorization are considerable, as each subtype is vulnerable to experimental medicines in a distinct way. For example, for PARP inhibitors, strong SLFN11 expression is the dominant predictive biomarker at present [<a href="#B95-cancers-14-05305" class="usa-link" aria-describedby="B95-cancers-14-05305">95</a>].</p>
<p>Cardnell et al. investigated the action of BMN 673, a novel, PARP inhibitor. In SCLC, the DNA Repair score (including genes such as <em>BRCA</em>, <em>ATM</em>, <em>ATR</em>, <em>CHK</em>, <em>RAD50</em> and <em>FANC</em>) was shown to correlate with the response of PARPi. The DNA repair score has a high inverse correlation to BMN 673 IC50, which is consistent with the expression of specific DNA repair markers (Ï = âˆ’0.762, <em>P</em> = 0.037), corroborating the result that cell lines with the greatest overall expression of DNA repair makers are the most susceptible to BMN 673 [<a href="#B96-cancers-14-05305" class="usa-link" aria-describedby="B96-cancers-14-05305">96</a>]. Finally, common alterations in SCLC, such as MYC amplification, have been shown to correlate with response to DNA-targeting agents such as CHEK1 inhibitors and in combination with cisplatin and olaparib, providing a rationale that subtypes of SCLC could be more vulnerable to DDR inhibition [<a href="#B97-cancers-14-05305" class="usa-link" aria-describedby="B97-cancers-14-05305">97</a>]. Therefore, no specific DDR-related alterations have been found to be predictive of treatment response in SCLC. This could be due to the scarcity of DDR-related alterations in small cell lung cancer, as well as their minor biological role. Nevertheless, non-DDR related biomarkers, such as SLFN11 and MYC amplification, are likely to be selected for further studies to assess their role in predicting response to different SCLC treatments, including PARPi.</p></section><section id="sec6-cancers-14-05305"><h2 class="pmc_sec_title">6. Clinical Relevance of Targeting HR Pathway in Patients with HRD in SCLC</h2>
<p>PARP inhibitors have been widely studied in SCLC. A phase 1, dose-escalation, two-part trial evaluated the efficacy of the PARP inhibitor talazoparib (MDV3800, BMN 673, talzenna, Pfizer). The study enrolled 23 patients with SCLC who were treated with 1 mg/day of talazoparib. Only two patients showed partial response and four patients had stable disease (SD) of at least 16 weeks [<a href="#B98-cancers-14-05305" class="usa-link" aria-describedby="B98-cancers-14-05305">98</a>]. In a phase-2 STOMP trial, olaparib was studied as a maintenance treatment for 220 patients with chemo-responsive SCLC. Two regimens of olaparib were investigated: 300 mg twice daily and 200 mg three times daily. There was no significant difference in PFS or OS between placebo and both treatment groups [<a href="#B99-cancers-14-05305" class="usa-link" aria-describedby="B99-cancers-14-05305">99</a>]. Veliparib was also studied in combination with platinum-based drugs. A phase 1 dose-escalation study evaluated the combination of veliparib with carboplatin and etoposide. In 25 patients with extensive-stage SCLC, complete responses (CR) and partial responses (PR) were observed in 64% of patients [<a href="#B100-cancers-14-05305" class="usa-link" aria-describedby="B100-cancers-14-05305">100</a>]. In a phase 2 trial that explored the efficacy of cisplatin and etoposide in combination with veliparib or placebo in extensive-stage SCLC. A total of 128 patients were enrolled in the study. The addition of veliparib to the regimen moderately improved outcomes for the patients with the median PFS for the veliparib arm versus the placebo arm of 6.1 versus 5.5 months. The median OS was 10.3 versus 8.9 months [<a href="#B101-cancers-14-05305" class="usa-link" aria-describedby="B101-cancers-14-05305">101</a>]. In another study, patients with relapsed SCLC in TMZ and veliparib group showed no signficiant difference to the TMZ and placebo group in 4-month PFS and OS. However, ORR was significantly better in TMZ and veliparib group. As mentioned earlier, SLFN11 expression was correlated to the efficacy of TMZ and veliparib showing improved PFS and OS [<a href="#B94-cancers-14-05305" class="usa-link" aria-describedby="B94-cancers-14-05305">94</a>]. Olaparib was also investigated in the combination with TMZ in a phase 1/2 study. The ORR was 41.7%, median PFS was 4.2 and median OS was 8.5 months [<a href="#B102-cancers-14-05305" class="usa-link" aria-describedby="B102-cancers-14-05305">102</a>]. PARPi (veliparib and talazoparib) were also shown to radiosensitize SCLC cell lines, and talazoparib was proven to be superior in this regard, providing a rationale for the design of trials combining PARPi with radiation therapy [<a href="#B103-cancers-14-05305" class="usa-link" aria-describedby="B103-cancers-14-05305">103</a>].</p>
<p>PARPi are currently also being investigated in combination with targeted therapy [<a href="#B104-cancers-14-05305" class="usa-link" aria-describedby="B104-cancers-14-05305">104</a>]. Checkpoint kinase 1 (CHK1) inhibitor prexasertib (LY2606368) increased the efficacy of olaparib in cell lines as well as xenograft models. This combination decreased viability and caused tumor regression [<a href="#B97-cancers-14-05305" class="usa-link" aria-describedby="B97-cancers-14-05305">97</a>]. Olaparib was also studied in combination with the WEE1 G2 checkpoint kinase inhibitor AZD1775. In a xenograft model, this combination was shown to be superior to the standard therapy of cisplatin/etoposide [<a href="#B105-cancers-14-05305" class="usa-link" aria-describedby="B105-cancers-14-05305">105</a>]. In Murai, Junko et al.â€™s study in different cell lines, SLFN11 expression was inversely correlated with sensitivity to PARP-trapping inhibitors (olaparib and talazoparib). Therefore, the increase in SLFN11 expression with the use of ATR inhibitor (VE-821) was suggested to lead to the higher sensitivity to PARPi [<a href="#B63-cancers-14-05305" class="usa-link" aria-describedby="B63-cancers-14-05305">63</a>]. The use of EPZ011989 (EZH2 inhibitor) in cell lines also increased SLFN11 expression and could potentially confer higher sensitivity to PARPi [<a href="#B106-cancers-14-05305" class="usa-link" aria-describedby="B106-cancers-14-05305">106</a>].</p>
<p>Other PARPi combinations with different therapeutics are currently being studied. For example, there is an ongoing phase 2 study of cediranib in combination with olaparib in multiple cancer types including SCLC (<a href="https://clinicaltrials.gov/ct2/show/NCT02498613" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02498613</a>) [<a href="#B107-cancers-14-05305" class="usa-link" aria-describedby="B107-cancers-14-05305">107</a>]. This follows the evidence from other tumor types that combine olaparib and cediranib, which is a vascular growth epidermal factor (VGEF) inhibitor that has shown improved PFS and OS [<a href="#B108-cancers-14-05305" class="usa-link" aria-describedby="B108-cancers-14-05305">108</a>]. Moreover, cediranib was found in breast and ovarian cancer xenografts to suppress the expression of BRCA1/2 and RAD51, inducing HRD state [<a href="#B109-cancers-14-05305" class="usa-link" aria-describedby="B109-cancers-14-05305">109</a>]. Another combination with PI3K inhibitors has been proposed by Cardnell et al., who showed, using a reverse-phase protein array, that PI3K/mTOR pathway (p-mTOR, pAKT, and pS6) is highly upregulated following the PARPi treatment. They hypothesize that this could be due to decreased ATP usage and a decrease in stress response signaling via liver kinase B1 (LKB1). Thus, they proposed combining talazoparib and BKM-120, and the effect was proven in vitro [<a href="#B110-cancers-14-05305" class="usa-link" aria-describedby="B110-cancers-14-05305">110</a>].</p>
<p>Immunotherapy shows a durable response in only a small fraction of patients with SCLC. This response could be defined by immune tumor subtype. Therefore, using a combination therapy that could reprogram the tumor microenvironment to be more sensitive to immunotherapy represents a possible avenue to be explored. PARPi have been described to increase the accumulation of cytosolic DNA fragments that activated the DNA-sensing cGASâ€“STING pathway and stimulated the production of type-1 IFNs. This, in turn, stimulates antitumor immunity and-infiltrating lymphocytes, which could be further amplified using checkpoint inhibitors [<a href="#B111-cancers-14-05305" class="usa-link" aria-describedby="B111-cancers-14-05305">111</a>]. A study showed that PARPi upregulated PD-L1 expression in breast cancer cell lines and animal models, which led to higher anticancer immunity. It was also shown that the combination of PARPi and anti-PD-L1 therapy had a significantly increased therapeutic efficacy in vivo [<a href="#B71-cancers-14-05305" class="usa-link" aria-describedby="B71-cancers-14-05305">71</a>]. PARPi were studied in combination with durvalumab. Patients with recurrent SCLC were included in a single-arm, phase 2 study (<a href="https://clinicaltrials.gov/ct2/show/NCT02484404" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02484404</a>) and were given durvalumab, 1500 mg, every 4 weeks, and olaparib, 300 mg, twice a day. However, the trial combination did not reach the effectiveness threshold. Biopsy specimens taken before and during therapy revealed that tumor immunological phenotypes may be important for SCLC responses to immune checkpoint blockade combinations [<a href="#B112-cancers-14-05305" class="usa-link" aria-describedby="B112-cancers-14-05305">112</a>]. At present, rucaparib is being investigated in combination with anti-PD-1 drug nivolumab in several phase 1/2/3 studies in different cancer types, including SCLC [<a href="#B113-cancers-14-05305" class="usa-link" aria-describedby="B113-cancers-14-05305">113</a>]. Finally, talazoparib is currently being tested in a phase 2 rial in combination with atezolizumab, to determine if this combination would be superior to atezolizumab maintenance in patients with extensive SCLC who have SLFN11-positive tumors (<a href="https://clinicaltrials.gov/ct2/show/NCT04334941" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT04334941</a>).</p>
<p>A major potential limiting factor for the combination of PARPi with immunotherapy is its safety profile, as the majority of patients could develop side effects, with about one third of patients possibly experiencing grade 3/4 side effects [<a href="#B114-cancers-14-05305" class="usa-link" aria-describedby="B114-cancers-14-05305">114</a>]. Therefore, further studies are essential to investigate the safety profile of combination PARPi and immunotherapy, especially given that different PARPi have distinct potency and overlapping side effects with checkpoint blockade (such as hepatitis).</p></section><section id="sec7-cancers-14-05305"><h2 class="pmc_sec_title">7. Conclusions</h2>
<p>The DNA-Damage Repair (DDR) pathways consists of multiple genes that are involved in maintaining genomic stability. Disruption in DDR pathways can lead to cancer progression, and provides the rationale for exploiting repair deficiencies through therapeutic intervention such as in breast and ovarian cancers. The role of DDR in lung cancer is unclear and requires further investigation due to the prevalence of DDR-related alterations in lung cancer (specifically in NSCLC). Further validation is needed to confirm DDR pathway alterations as a predictive marker of immunotherapy response in NSCLC. However, if confirmed, this will be an extremely important marker to consider when selecting patients for clinical trials and potential PARPi combination therapy with immunotherapy. In contrast, DDR alterations appear to be less reliable as a predictive biomarker of response to chemotherapy or radiation therapy in NSCLC. In SCLC, the available evidence suggests no apparent role of DDR alterations as predictors of response to treatment; however, the presence of surrogate non-DDR-related markers (such as SLFN11) could help select for patients responsive to PARP inhibition.</p>
<p>More focused research efforts are essential to better understand the biological implications of DDR alterations in both NSCLC and SCLC, as there has been no demonstration of the efficacy of DDR-targeting agents, despite several clinical trials. Understanding how DDR pathway alterations and treatments remodel the tumor microenvironment will provider future opportunities to study additional novel therapeutic strategies that may impact outcomes in patients with lung cancer who harbor DDR-pathway alterations.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<p>NSCLC: Non-small cell lung cancer; SCLC: small cell lung cancer; LAUD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PD-L1: programmed death-ligand 1; Os: overall survival; ICI: immune checkpoint inhibitors; DDR: DNA-damage repair; TCGA: The Cancer Genome Atlas; NER: nucleotide excision repair; BER: base excision repair; DR: direct repair; HR: homologous recombination; NHEJ: non-homologous end joining; MMR: mismatch repair; GG-NER: global genomic nucleotide excision repair; TC-NER: transcription-coupled nucleotide excision repair; PARP: poly(ADP-ribose) polymerase; DSB: DNA double-strand breaks; HRD: homologous recombination deficiency; LOH: loss of heterozygosity; NtAI: number of telomeric allelic imbalances; LST: large-scale transitions; PARPi: PARP inhibitors; FA: Fanconi Anemia; PFS: progression-free survival; DDB2: DNA damage binding protein 2; TMB: tumor mutational burden; ORR: objective response rates; SLFN11: Schlafen family member 11; TMZ: temozolomide; SD: stable disease; VGEF: vascular growth epidermal factor.</p></section><section id="app1-cancers-14-05305" class="app"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<p>The following supporting information can be downloaded at: <a href="https://www.mdpi.com/article/10.3390/cancers14215305/s1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.mdpi.com/article/10.3390/cancers14215305/s1</a>, Table S1: Select clinical trials of DNA-damage repair targeted agents in clinical trials in solid tumors including non-small cell lung cancer.</p>
<section class="sm xbox font-sm" id="cancers-14-05305-s001"><div class="media p"><div class="caption">
<a href="/articles/instance/9654807/bin/cancers-14-05305-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (144.4KB, zip) </sup>
</div></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization: K.K. and Y.B.; data curation: K.K., M.F.F., M.K., A.G. and D.D.; writingâ€”original draft preparation: K.K., M.F.F., M.K., A.G. and D.D.; review and editing: K.K., M.F.F., M.K., A.G., D.D., I.T., J.D.P., F.W. and Y.B.; figure creation: K.K.; table creation: K.K., M.F.F., M.K., A.G. and D.D.; supervision: K.K., J.D.P., F.W. and Y.B. All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>K.K. declares no conflict of interest; M.F.F. declares no conflict of interest; M.K. declares no conflict of interest; A.G. declares no conflict of interest; D.D. declares no conflict of interest; I.T. declares no conflict of interest; J.D.P: Jyoti D. Patel reports grants from Bristol-Myers Squibb and personal fees from AbbVie, AstraZeneca, Eli Lilly &amp; Company, Genentech USA, Inc., and Takeda Oncology outside the submitted work; F.W. declares no conflict of interest; Y.B.: Amgen and Regeneron (speaker), G1 therapeutics (advisory board).</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>Y.B. and I.T. are supported by NIH R01 CA218802 grant and by 2022 Translation Bridge Award from Northwestern University and Lurie Cancer Center. Y.B., I.T. and J.P. were supported by the NCI Core Grant P30 CA060553 (to Robert H Lurie Comprehensive Cancer Center at Northwestern University).</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Publisherâ€™s Note:</strong> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-cancers-14-05305">
<span class="label">1.</span><cite>Thai A.A., Solomon B.J., Sequist L.V., Gainor J.F., Heist R.S. Lung cancer. Lancet. 2021;398:535â€“554. doi: 10.1016/S0140-6736(21)00312-3.</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)00312-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34273294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Lung%20cancer&amp;author=A.A.%20Thai&amp;author=B.J.%20Solomon&amp;author=L.V.%20Sequist&amp;author=J.F.%20Gainor&amp;author=R.S.%20Heist&amp;volume=398&amp;publication_year=2021&amp;pages=535-554&amp;pmid=34273294&amp;doi=10.1016/S0140-6736(21)00312-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-cancers-14-05305">
<span class="label">2.</span><cite>Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394â€“424. doi: 10.3322/caac.21492.</cite> [<a href="https://doi.org/10.3322/caac.21492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30207593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=CA%20Cancer%20J.%20Clin.&amp;title=Global%20cancer%20statistics%202018:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries&amp;author=F.%20Bray&amp;author=J.%20Ferlay&amp;author=I.%20Soerjomataram&amp;author=R.L.%20Siegel&amp;author=L.A.%20Torre&amp;volume=68&amp;publication_year=2018&amp;pages=394-424&amp;pmid=30207593&amp;doi=10.3322/caac.21492&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-cancers-14-05305">
<span class="label">3.</span><cite>Skoulidis F., Heymach J.V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat. Rev. Cancer. 2019;19:495â€“509. doi: 10.1038/s41568-019-0179-8.</cite> [<a href="https://doi.org/10.1038/s41568-019-0179-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7043073/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31406302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Cancer&amp;title=Co-occurring%20genomic%20alterations%20in%20non-small-cell%20lung%20cancer%20biology%20and%20therapy&amp;author=F.%20Skoulidis&amp;author=J.V.%20Heymach&amp;volume=19&amp;publication_year=2019&amp;pages=495-509&amp;pmid=31406302&amp;doi=10.1038/s41568-019-0179-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-cancers-14-05305">
<span class="label">4.</span><cite>Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., Cho J., Suh J., Capelletti M., Sivachenko A., et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell. 2012;150:1107â€“1120. doi: 10.1016/j.cell.2012.08.029.</cite> [<a href="https://doi.org/10.1016/j.cell.2012.08.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3557932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22980975/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Mapping%20the%20Hallmarks%20of%20Lung%20Adenocarcinoma%20with%20Massively%20Parallel%20Sequencing&amp;author=M.%20Imielinski&amp;author=A.H.%20Berger&amp;author=P.S.%20Hammerman&amp;author=B.%20Hernandez&amp;author=T.J.%20Pugh&amp;volume=150&amp;publication_year=2012&amp;pages=1107-1120&amp;pmid=22980975&amp;doi=10.1016/j.cell.2012.08.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5-cancers-14-05305">
<span class="label">5.</span><cite>Cancer Genome Atlas Research Network  Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519â€“525. doi: 10.1038/nature11404.</cite> [<a href="https://doi.org/10.1038/nature11404" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3466113/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22960745/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20genomic%20characterization%20of%20squamous%20cell%20lung%20cancers&amp;volume=489&amp;publication_year=2012&amp;pages=519-525&amp;pmid=22960745&amp;doi=10.1038/nature11404&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-cancers-14-05305">
<span class="label">6.</span><cite>Skoulidis F., Li B.T., Dy G.K., Price T.J., Falchook G.S., Wolf J., Italiano A., Schuler M., Borghaei H., Barlesi F., et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl. J. Med. 2021;384:2371â€“2381. doi: 10.1056/NEJMoa2103695.</cite> [<a href="https://doi.org/10.1056/NEJMoa2103695" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9116274/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34096690/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Sotorasib%20for%20Lung%20Cancers%20with%20KRAS%20p.G12C%20Mutation&amp;author=F.%20Skoulidis&amp;author=B.T.%20Li&amp;author=G.K.%20Dy&amp;author=T.J.%20Price&amp;author=G.S.%20Falchook&amp;volume=384&amp;publication_year=2021&amp;pages=2371-2381&amp;pmid=34096690&amp;doi=10.1056/NEJMoa2103695&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-cancers-14-05305">
<span class="label">7.</span><cite>Reck M., RodrÃ­guez-Abreu D., Robinson A.G., Hui R., CsÅ‘szi T., FÃ¼lÃ¶p A., Gottfried M., Peled N., Tafreshi A., Cuffe S., et al.  Pembrolizumab versus Chemotherapy for PD-L1â€“Positive Nonâ€“Small-Cell Lung Cancer. N. Engl. J. Med. 2016;375:1823â€“1833. doi: 10.1056/NEJMoa1606774.</cite> [<a href="https://doi.org/10.1056/NEJMoa1606774" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27718847/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Pembrolizumab%20versus%20Chemotherapy%20for%20PD-L1%E2%80%93Positive%20Non%E2%80%93Small-Cell%20Lung%20Cancer&amp;author=M.%20Reck&amp;author=D.%20Rodr%C3%ADguez-Abreu&amp;author=A.G.%20Robinson&amp;author=R.%20Hui&amp;author=T.%20Cs%C5%91szi&amp;volume=375&amp;publication_year=2016&amp;pages=1823-1833&amp;pmid=27718847&amp;doi=10.1056/NEJMoa1606774&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-cancers-14-05305">
<span class="label">8.</span><cite>Felip E., Altorki N., Zhou C., CsÅ‘szi T., Vynnychenko I., Goloborodko O., Luft A., Akopov A., Martinez-Marti A., Kenmotsu H., et al.  IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IBâ€“IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344â€“1357. doi: 10.1016/S0140-6736(21)02098-5.</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)02098-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34555333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=IMpower010%20Investigators.%20Adjuvant%20atezolizumab%20after%20adjuvant%20chemotherapy%20in%20resected%20stage%20IB%E2%80%93IIIA%20non-small-cell%20lung%20cancer%20(IMpower010):%20A%20randomised,%20multicentre,%20open-label,%20phase%203%20trial&amp;author=E.%20Felip&amp;author=N.%20Altorki&amp;author=C.%20Zhou&amp;author=T.%20Cs%C5%91szi&amp;author=I.%20Vynnychenko&amp;volume=398&amp;publication_year=2021&amp;pages=1344-1357&amp;pmid=34555333&amp;doi=10.1016/S0140-6736(21)02098-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-cancers-14-05305">
<span class="label">9.</span><cite>Akinboro O., Vallejo J.J., Mishra-Kalyani P.S., Larkins E.A., Drezner N.L., Tang S., Pazdur R., Beaver J.A., Harpreet S. Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1â€“49%: FDA pooled analysis. J. Clin. Oncol. 2021;39:9001. doi: 10.1200/JCO.2021.39.15_suppl.9001.</cite> [<a href="https://doi.org/10.1200/JCO.2021.39.15_suppl.9001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Outcomes%20of%20anti-PD-(L1)%20therapy%20in%20combination%20with%20chemotherapy%20versus%20immunotherapy%20(IO)%20alone%20for%20first-line%20(1L)%20treatment%20of%20advanced%20non-small%20cell%20lung%20cancer%20(NSCLC)%20with%20PD-L1%20score%201%E2%80%9349%:%20FDA%20pooled%20analysis&amp;author=O.%20Akinboro&amp;author=J.J.%20Vallejo&amp;author=P.S.%20Mishra-Kalyani&amp;author=E.A.%20Larkins&amp;author=N.L.%20Drezner&amp;volume=39&amp;publication_year=2021&amp;pages=9001&amp;doi=10.1200/JCO.2021.39.15_suppl.9001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-cancers-14-05305">
<span class="label">10.</span><cite>Knijnenburg T.A., Wang L., Zimmermann M.T., Chambwe N., Gao G.F., Cherniack A.D., Fan H., Shen H., Way G.P., Greene C.S., et al.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23:239â€“254.e6. doi: 10.1016/j.celrep.2018.03.076.</cite> [<a href="https://doi.org/10.1016/j.celrep.2018.03.076" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5961503/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29617664/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Rep.&amp;title=Genomic%20and%20Molecular%20Landscape%20of%20DNA%20Damage%20Repair%20Deficiency%20across%20The%20Cancer%20Genome%20Atlas&amp;author=T.A.%20Knijnenburg&amp;author=L.%20Wang&amp;author=M.T.%20Zimmermann&amp;author=N.%20Chambwe&amp;author=G.F.%20Gao&amp;volume=23&amp;publication_year=2018&amp;pages=239-254.e6&amp;pmid=29617664&amp;doi=10.1016/j.celrep.2018.03.076&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-cancers-14-05305">
<span class="label">11.</span><cite>Burgess J.T., Rose M., Boucher D., Plowman J., Molloy C., Fisher M., Oâ€™Leary C., Richard D.J., Oâ€™Byrne K.J., Bolderson E. The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer. Front. Oncol. 2020;10:1256. doi: 10.3389/fonc.2020.01256.</cite> [<a href="https://doi.org/10.3389/fonc.2020.01256" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7399071/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32850380/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=The%20Therapeutic%20Potential%20of%20DNA%20Damage%20Repair%20Pathways%20and%20Genomic%20Stability%20in%20Lung%20Cancer&amp;author=J.T.%20Burgess&amp;author=M.%20Rose&amp;author=D.%20Boucher&amp;author=J.%20Plowman&amp;author=C.%20Molloy&amp;volume=10&amp;publication_year=2020&amp;pages=1256&amp;pmid=32850380&amp;doi=10.3389/fonc.2020.01256&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-cancers-14-05305">
<span class="label">12.</span><cite>Melis J.P., van Steeg H., Luijten M. Oxidative DNA Damage and Nucleotide Excision Repair. Antioxid. Redox Signal. 2013;18:2409â€“2419. doi: 10.1089/ars.2012.5036.</cite> [<a href="https://doi.org/10.1089/ars.2012.5036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3671630/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23216312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antioxid.%20Redox%20Signal.&amp;title=Oxidative%20DNA%20Damage%20and%20Nucleotide%20Excision%20Repair&amp;author=J.P.%20Melis&amp;author=H.%20van%20Steeg&amp;author=M.%20Luijten&amp;volume=18&amp;publication_year=2013&amp;pages=2409-2419&amp;pmid=23216312&amp;doi=10.1089/ars.2012.5036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-cancers-14-05305">
<span class="label">13.</span><cite>Beard W.A., Horton J.K., Prasad R., Wilson S.H. Eukaryotic Base Excision Repair: New Approaches Shine Light on Mechanism. Annu. Rev. Biochem. 2019;88:137â€“162. doi: 10.1146/annurev-biochem-013118-111315.</cite> [<a href="https://doi.org/10.1146/annurev-biochem-013118-111315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8956022/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31220977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu.%20Rev.%20Biochem.&amp;title=Eukaryotic%20Base%20Excision%20Repair:%20New%20Approaches%20Shine%20Light%20on%20Mechanism&amp;author=W.A.%20Beard&amp;author=J.K.%20Horton&amp;author=R.%20Prasad&amp;author=S.H.%20Wilson&amp;volume=88&amp;publication_year=2019&amp;pages=137-162&amp;pmid=31220977&amp;doi=10.1146/annurev-biochem-013118-111315&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-cancers-14-05305">
<span class="label">14.</span><cite>Takaoka M., Miki Y. BRCA1 gene: Function and deficiency. Int. J. Clin. Oncol. 2017;23:36â€“44. doi: 10.1007/s10147-017-1182-2.</cite> [<a href="https://doi.org/10.1007/s10147-017-1182-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28884397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Clin.%20Oncol.&amp;title=BRCA1%20gene:%20Function%20and%20deficiency&amp;author=M.%20Takaoka&amp;author=Y.%20Miki&amp;volume=23&amp;publication_year=2017&amp;pages=36-44&amp;pmid=28884397&amp;doi=10.1007/s10147-017-1182-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-cancers-14-05305">
<span class="label">15.</span><cite>Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646â€“674. doi: 10.1016/j.cell.2011.02.013.</cite> [<a href="https://doi.org/10.1016/j.cell.2011.02.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21376230/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Hallmarks%20of%20cancer:%20The%20next%20generation&amp;author=D.%20Hanahan&amp;author=R.A.%20Weinberg&amp;volume=144&amp;publication_year=2011&amp;pages=646-674&amp;pmid=21376230&amp;doi=10.1016/j.cell.2011.02.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-cancers-14-05305">
<span class="label">16.</span><cite>PiliÃ© P.G., Tang C., Mills G.B., Yap T.A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 2019;16:81â€“104. doi: 10.1038/s41571-018-0114-z.</cite> [<a href="https://doi.org/10.1038/s41571-018-0114-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8327299/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30356138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;title=State-of-the-art%20strategies%20for%20targeting%20the%20DNA%20damage%20response%20in%20cancer&amp;author=P.G.%20Pili%C3%A9&amp;author=C.%20Tang&amp;author=G.B.%20Mills&amp;author=T.A.%20Yap&amp;volume=16&amp;publication_year=2019&amp;pages=81-104&amp;pmid=30356138&amp;doi=10.1038/s41571-018-0114-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-cancers-14-05305">
<span class="label">17.</span><cite>Nguyen L.W.M., Martens J., Van Hoeck A., Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 2020;11:5584. doi: 10.1038/s41467-020-19406-4.</cite> [<a href="https://doi.org/10.1038/s41467-020-19406-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7643118/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33149131/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Pan-cancer%20landscape%20of%20homologous%20recombination%20deficiency&amp;author=L.W.M.%20Nguyen&amp;author=J.%20Martens&amp;author=A.%20Van%20Hoeck&amp;author=E.%20Cuppen&amp;volume=11&amp;publication_year=2020&amp;pages=5584&amp;pmid=33149131&amp;doi=10.1038/s41467-020-19406-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-cancers-14-05305">
<span class="label">18.</span><cite>Abkevich V., Timms K.M., Hennessy B.T., Potter J., Carey M.S., Meyer L.A., Smith-McCune K., Broaddus R., Lu K.H., Chen J., et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer. 2012;107:1776â€“1782. doi: 10.1038/bjc.2012.451.</cite> [<a href="https://doi.org/10.1038/bjc.2012.451" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3493866/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23047548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Cancer&amp;title=Patterns%20of%20genomic%20loss%20of%20heterozygosity%20predict%20homologous%20recombination%20repair%20defects%20in%20epithelial%20ovarian%20cancer&amp;author=V.%20Abkevich&amp;author=K.M.%20Timms&amp;author=B.T.%20Hennessy&amp;author=J.%20Potter&amp;author=M.S.%20Carey&amp;volume=107&amp;publication_year=2012&amp;pages=1776-1782&amp;pmid=23047548&amp;doi=10.1038/bjc.2012.451&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-cancers-14-05305">
<span class="label">19.</span><cite>Popova T., ManiÃ© E., Rieunier G., Caux-Moncoutier V., Tirapo C., Dubois T., Delattre O., Sigal-Zafrani B., Bollet M., Longy M., et al.  Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation. Cancer Res. 2012;72:5454â€“5462. doi: 10.1158/0008-5472.can-12-1470.</cite> [<a href="https://doi.org/10.1158/0008-5472.can-12-1470" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22933060/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=Ploidy%20and%20Large-Scale%20Genomic%20Instability%20Consistently%20Identify%20Basal-like%20Breast%20Carcinomas%20with%20BRCA1/2%20Inactivation&amp;author=T.%20Popova&amp;author=E.%20Mani%C3%A9&amp;author=G.%20Rieunier&amp;author=V.%20Caux-Moncoutier&amp;author=C.%20Tirapo&amp;volume=72&amp;publication_year=2012&amp;pages=5454-5462&amp;pmid=22933060&amp;doi=10.1158/0008-5472.can-12-1470&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-cancers-14-05305">
<span class="label">20.</span><cite>Birkbak N.J., Wang Z.C., Kim J.-Y., Eklund A.C., Li Q., Tian R., Bowman-Colin C., Li Y., Greene-Colozzi A., Iglehart J.D., et al.  Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. Cancer Discov. 2012;2:366â€“375. doi: 10.1158/2159-8290.CD-11-0206.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-11-0206" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3806629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22576213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Telomeric%20Allelic%20Imbalance%20Indicates%20Defective%20DNA%20Repair%20and%20Sensitivity%20to%20DNA-Damaging%20Agents&amp;author=N.J.%20Birkbak&amp;author=Z.C.%20Wang&amp;author=J.-Y.%20Kim&amp;author=A.C.%20Eklund&amp;author=Q.%20Li&amp;volume=2&amp;publication_year=2012&amp;pages=366-375&amp;pmid=22576213&amp;doi=10.1158/2159-8290.CD-11-0206&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-cancers-14-05305">
<span class="label">21.</span><cite>Robson M., Im S.A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N., Armstrong A., et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377:523â€“533. doi: 10.1056/NEJMoa1706450.</cite> [<a href="https://doi.org/10.1056/NEJMoa1706450" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28578601/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Olaparib%20for%20Metastatic%20Breast%20Cancer%20in%20Patients%20with%20a%20Germline%20BRCA%20Mutation&amp;author=M.%20Robson&amp;author=S.A.%20Im&amp;author=E.%20Senkus&amp;author=B.%20Xu&amp;author=S.M.%20Domchek&amp;volume=377&amp;publication_year=2017&amp;pages=523-533&amp;pmid=28578601&amp;doi=10.1056/NEJMoa1706450&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-cancers-14-05305">
<span class="label">22.</span><cite>Litton J., Hurvitz S., Mina L., Rugo H., Lee K.-H., GonÃ§alves A., Diab S., Woodward N., Goodwin A., Yerushalmi R., et al.  Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: Final overall survival results from the EMBRACA trial. Ann. Oncol. 2020;31:1526â€“1535. doi: 10.1016/j.annonc.2020.08.2098.</cite> [<a href="https://doi.org/10.1016/j.annonc.2020.08.2098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10649377/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32828825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Talazoparib%20versus%20chemotherapy%20in%20patients%20with%20germline%20BRCA1/2-mutated%20HER2-negative%20advanced%20breast%20cancer:%20Final%20overall%20survival%20results%20from%20the%20EMBRACA%20trial&amp;author=J.%20Litton&amp;author=S.%20Hurvitz&amp;author=L.%20Mina&amp;author=H.%20Rugo&amp;author=K.-H.%20Lee&amp;volume=31&amp;publication_year=2020&amp;pages=1526-1535&amp;pmid=32828825&amp;doi=10.1016/j.annonc.2020.08.2098&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-cancers-14-05305">
<span class="label">23.</span><cite>Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K.N., Sartor O., Agarwal N., Olmos D., et al.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020;383:2345â€“2357. doi: 10.1056/NEJMoa2022485.</cite> [<a href="https://doi.org/10.1056/NEJMoa2022485" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32955174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Survival%20with%20Olaparib%20in%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&amp;author=M.%20Hussain&amp;author=J.%20Mateo&amp;author=K.%20Fizazi&amp;author=F.%20Saad&amp;author=N.%20Shore&amp;volume=383&amp;publication_year=2020&amp;pages=2345-2357&amp;pmid=32955174&amp;doi=10.1056/NEJMoa2022485&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-cancers-14-05305">
<span class="label">24.</span><cite>Yoshida K., Gowers K.H.C., Lee-Six H., Chandrasekharan D.P., Coorens T., Maughan E.F., Beal K., Menzies A., Millar F.R., Anderson E., et al.  Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020;578:266â€“272. doi: 10.1038/s41586-020-1961-1.</cite> [<a href="https://doi.org/10.1038/s41586-020-1961-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7021511/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31996850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Tobacco%20smoking%20and%20somatic%20mutations%20in%20human%20bronchial%20epithelium&amp;author=K.%20Yoshida&amp;author=K.H.C.%20Gowers&amp;author=H.%20Lee-Six&amp;author=D.P.%20Chandrasekharan&amp;author=T.%20Coorens&amp;volume=578&amp;publication_year=2020&amp;pages=266-272&amp;pmid=31996850&amp;doi=10.1038/s41586-020-1961-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-cancers-14-05305">
<span class="label">25.</span><cite>Hopkin J.M., Evans H.J. Cigarette smoke-induced DNA damage and lung cancer risks. Nature. 1980;283:388â€“390. doi: 10.1038/283388a0.</cite> [<a href="https://doi.org/10.1038/283388a0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7352014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Cigarette%20smoke-induced%20DNA%20damage%20and%20lung%20cancer%20risks&amp;author=J.M.%20Hopkin&amp;author=H.J.%20Evans&amp;volume=283&amp;publication_year=1980&amp;pages=388-390&amp;pmid=7352014&amp;doi=10.1038/283388a0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B26-cancers-14-05305">
<span class="label">26.</span><cite>Zhao H., Albino A.P., Jorgensen E., Traganos F., Darzynkiewicz Z. DNA damage response induced by tobacco smoke in normal human bronchial epithelial and A549 pulmonary adenocarcinoma cells assessed by laser scanning cytometry. Cytom. Part A. 2009;75:840â€“847. doi: 10.1002/cyto.a.20778.</cite> [<a href="https://doi.org/10.1002/cyto.a.20778" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2814777/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19658174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cytom.%20Part%20A&amp;title=DNA%20damage%20response%20induced%20by%20tobacco%20smoke%20in%20normal%20human%20bronchial%20epithelial%20and%20A549%20pulmonary%20adenocarcinoma%20cells%20assessed%20by%20laser%20scanning%20cytometry&amp;author=H.%20Zhao&amp;author=A.P.%20Albino&amp;author=E.%20Jorgensen&amp;author=F.%20Traganos&amp;author=Z.%20Darzynkiewicz&amp;volume=75&amp;publication_year=2009&amp;pages=840-847&amp;pmid=19658174&amp;doi=10.1002/cyto.a.20778&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B27-cancers-14-05305">
<span class="label">27.</span><cite>Heeke A.L., Pishvaian M.J., Lynce F., Xiu J., Brody J.R., Chen W.-J., Baker T.M., Marshall J.L., Isaacs C. Prevalence of Homologous Recombinationâ€“Related Gene Mutations Across Multiple Cancer Types. JCO Precis. Oncol. 2018;2018:1â€“13. doi: 10.1200/PO.17.00286.</cite> [<a href="https://doi.org/10.1200/PO.17.00286" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6139373/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30234181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precis.%20Oncol.&amp;title=Prevalence%20of%20Homologous%20Recombination%E2%80%93Related%20Gene%20Mutations%20Across%20Multiple%20Cancer%20Types&amp;author=A.L.%20Heeke&amp;author=M.J.%20Pishvaian&amp;author=F.%20Lynce&amp;author=J.%20Xiu&amp;author=J.R.%20Brody&amp;volume=2018&amp;publication_year=2018&amp;pages=1-13&amp;pmid=30234181&amp;doi=10.1200/PO.17.00286&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B28-cancers-14-05305">
<span class="label">28.</span><cite>Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al.  Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069â€“1075. doi: 10.1038/nature07423.</cite> [<a href="https://doi.org/10.1038/nature07423" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2694412/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18948947/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Somatic%20mutations%20affect%20key%20pathways%20in%20lung%20adenocarcinoma&amp;author=L.%20Ding&amp;author=G.%20Getz&amp;author=D.A.%20Wheeler&amp;author=E.R.%20Mardis&amp;author=M.D.%20McLellan&amp;volume=455&amp;publication_year=2008&amp;pages=1069-1075&amp;pmid=18948947&amp;doi=10.1038/nature07423&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B29-cancers-14-05305">
<span class="label">29.</span><cite>Parry E.M., Gable D.L., Stanley S.E., Khalil S.E., Antonescu V., Florea L., Armanios M. Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma. J. Thorac. Oncol. 2017;12:1673â€“1678. doi: 10.1016/j.jtho.2017.08.011.</cite> [<a href="https://doi.org/10.1016/j.jtho.2017.08.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5659909/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28843361/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Germline%20Mutations%20in%20DNA%20Repair%20Genes%20in%20Lung%20Adenocarcinoma&amp;author=E.M.%20Parry&amp;author=D.L.%20Gable&amp;author=S.E.%20Stanley&amp;author=S.E.%20Khalil&amp;author=V.%20Antonescu&amp;volume=12&amp;publication_year=2017&amp;pages=1673-1678&amp;pmid=28843361&amp;doi=10.1016/j.jtho.2017.08.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B30-cancers-14-05305">
<span class="label">30.</span><cite>Campbell J.D., Alexandrov A., Kim J., Wala J., Berger A.H., Pedamallu C.S., Shukla S.A., Guo G., Brooks A.N., Murray B.A., et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 2016;48:607â€“616. doi: 10.1038/ng.3564.</cite> [<a href="https://doi.org/10.1038/ng.3564" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4884143/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27158780/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Genet.&amp;title=Distinct%20patterns%20of%20somatic%20genome%20alterations%20in%20lung%20adenocarcinomas%20and%20squamous%20cell%20carcinomas&amp;author=J.D.%20Campbell&amp;author=A.%20Alexandrov&amp;author=J.%20Kim&amp;author=J.%20Wala&amp;author=A.H.%20Berger&amp;volume=48&amp;publication_year=2016&amp;pages=607-616&amp;pmid=27158780&amp;doi=10.1038/ng.3564&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B31-cancers-14-05305">
<span class="label">31.</span><cite>Yoshino T., Pentheroudakis G., Mishima S., Overman M., Yeh K.-H., Baba E., Naito Y., Calvo F., Saxena A., Chen L.-T., et al.  JSCOâ€”ESMOâ€”ASCOâ€”JSMOâ€”TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann. Oncol. 2020;31:861â€“872. doi: 10.1016/j.annonc.2020.03.299.</cite> [<a href="https://doi.org/10.1016/j.annonc.2020.03.299" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32272210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=JSCO%E2%80%94ESMO%E2%80%94ASCO%E2%80%94JSMO%E2%80%94TOS:%20International%20expert%20consensus%20recommendations%20for%20tumour-agnostic%20treatments%20in%20patients%20with%20solid%20tumours%20with%20microsatellite%20instability%20or%20NTRK%20fusions&amp;author=T.%20Yoshino&amp;author=G.%20Pentheroudakis&amp;author=S.%20Mishima&amp;author=M.%20Overman&amp;author=K.-H.%20Yeh&amp;volume=31&amp;publication_year=2020&amp;pages=861-872&amp;pmid=32272210&amp;doi=10.1016/j.annonc.2020.03.299&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B32-cancers-14-05305">
<span class="label">32.</span><cite>Waqar S.N., Devarakonda S.H.K., Michel L.S., Maggi L.B., Watson M., Guebert K., Carpenter D., Sleckman B.P., Govindan R., Morgensztern D. BRCAness in non-small cell lung cancer (NSCLC) J. Clin. Oncol. 2014;32:11033. doi: 10.1200/jco.2014.32.15_suppl.11033.</cite> [<a href="https://doi.org/10.1200/jco.2014.32.15_suppl.11033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=BRCAness%20in%20non-small%20cell%20lung%20cancer%20(NSCLC)&amp;author=S.N.%20Waqar&amp;author=S.H.K.%20Devarakonda&amp;author=L.S.%20Michel&amp;author=L.B.%20Maggi&amp;author=M.%20Watson&amp;volume=32&amp;publication_year=2014&amp;pages=11033&amp;doi=10.1200/jco.2014.32.15_suppl.11033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B33-cancers-14-05305">
<span class="label">33.</span><cite>Ricciuti B., Recondo G., Spurr L.F., Li Y.Y., Lamberti G., Venkatraman D., Umeton R., Cherniack A.D., Nishino M., Sholl L.M., et al.  Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€“Small Cell Lung Cancer. Clin. Cancer Res. 2020;26:4135â€“4142. doi: 10.1158/1078-0432.CCR-19-3529.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-3529" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32332016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Impact%20of%20DNA%20Damage%20Response%20and%20Repair%20(DDR)%20Gene%20Mutations%20on%20Efficacy%20of%20PD-(L)1%20Immune%20Checkpoint%20Inhibition%20in%20Non%E2%80%93Small%20Cell%20Lung%20Cancer&amp;author=B.%20Ricciuti&amp;author=G.%20Recondo&amp;author=L.F.%20Spurr&amp;author=Y.Y.%20Li&amp;author=G.%20Lamberti&amp;volume=26&amp;publication_year=2020&amp;pages=4135-4142&amp;pmid=32332016&amp;doi=10.1158/1078-0432.CCR-19-3529&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B34-cancers-14-05305">
<span class="label">34.</span><cite>Helin K., Holm K., Niebuhr A., Eiberg H., Tommerup N., Hougaard S., Poulsen H.S., Spang-Thomsen M., NÃ¸rgaard P. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl. Acad. Sci. USA. 1997;94:6933â€“6938. doi: 10.1073/pnas.94.13.6933.</cite> [<a href="https://doi.org/10.1073/pnas.94.13.6933" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC21262/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9192669/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20USA&amp;title=Loss%20of%20the%20retinoblastoma%20protein-related%20p130%20protein%20in%20small%20cell%20lung%20carcinoma&amp;author=K.%20Helin&amp;author=K.%20Holm&amp;author=A.%20Niebuhr&amp;author=H.%20Eiberg&amp;author=N.%20Tommerup&amp;volume=94&amp;publication_year=1997&amp;pages=6933-6938&amp;pmid=9192669&amp;doi=10.1073/pnas.94.13.6933&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B35-cancers-14-05305">
<span class="label">35.</span><cite>Miller C.W., Simon K., Aslo A., Kok K., Yokota J., Buys C.H., Terada M., Koeffler H.P. p53 mutations in human lung tumors. Cancer Res. 1992;52:1695â€“1698.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/1312896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=p53%20mutations%20in%20human%20lung%20tumors&amp;author=C.W.%20Miller&amp;author=K.%20Simon&amp;author=A.%20Aslo&amp;author=K.%20Kok&amp;author=J.%20Yokota&amp;volume=52&amp;publication_year=1992&amp;pages=1695-1698&amp;pmid=1312896&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B36-cancers-14-05305">
<span class="label">36.</span><cite>Park S., Lee H., Lee B., Lee S.-H., Sun J.-M., Park W.-Y., Ahn J.S., Ahn M.-J., Park K. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. J. Thorac. Oncol. 2019;14:1640â€“1650. doi: 10.1016/j.jtho.2019.05.014.</cite> [<a href="https://doi.org/10.1016/j.jtho.2019.05.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31125737/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=DNA%20Damage%20Response%20and%20Repair%20Pathway%20Alteration%20and%20Its%20Association%20With%20Tumor%20Mutation%20Burden%20and%20Platinum-Based%20Chemotherapy%20in%20SCLC&amp;author=S.%20Park&amp;author=H.%20Lee&amp;author=B.%20Lee&amp;author=S.-H.%20Lee&amp;author=J.-M.%20Sun&amp;volume=14&amp;publication_year=2019&amp;pages=1640-1650&amp;pmid=31125737&amp;doi=10.1016/j.jtho.2019.05.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B37-cancers-14-05305">
<span class="label">37.</span><cite>Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., et al.  Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discov. 2012;2:798â€“811. doi: 10.1158/2159-8290.CD-12-0112.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-12-0112" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3567922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22961666/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Proteomic%20Profiling%20Identifies%20Dysregulated%20Pathways%20in%20Small%20Cell%20Lung%20Cancer%20and%20Novel%20Therapeutic%20Targets%20Including%20PARP1&amp;author=L.A.%20Byers&amp;author=J.%20Wang&amp;author=M.B.%20Nilsson&amp;author=J.%20Fujimoto&amp;author=P.%20Saintigny&amp;volume=2&amp;publication_year=2012&amp;pages=798-811&amp;pmid=22961666&amp;doi=10.1158/2159-8290.CD-12-0112&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B38-cancers-14-05305">
<span class="label">38.</span><cite>Pignon J.-P., Tribodet H., Scagliotti G.V., Douillard J.-Y., Shepherd F.A., Stephens R.J., Dunant A., Torri V., Rosell R., Seymour L., et al.  Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008;26:3552â€“3559. doi: 10.1200/JCO.2007.13.9030.</cite> [<a href="https://doi.org/10.1200/JCO.2007.13.9030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18506026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Lung%20Adjuvant%20Cisplatin%20Evaluation:%20A%20Pooled%20Analysis%20by%20the%20LACE%20Collaborative%20Group&amp;author=J.-P.%20Pignon&amp;author=H.%20Tribodet&amp;author=G.V.%20Scagliotti&amp;author=J.-Y.%20Douillard&amp;author=F.A.%20Shepherd&amp;volume=26&amp;publication_year=2008&amp;pages=3552-3559&amp;pmid=18506026&amp;doi=10.1200/JCO.2007.13.9030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B39-cancers-14-05305">
<span class="label">39.</span><cite>Cosaert J., Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br. J. Cancer. 2002;87:825â€“833. doi: 10.1038/sj.bjc.6600540.</cite> [<a href="https://doi.org/10.1038/sj.bjc.6600540" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2376170/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12373594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Cancer&amp;title=Platinum%20drugs%20in%20the%20treatment%20of%20non-small-cell%20lung%20cancer&amp;author=J.%20Cosaert&amp;author=E.%20Quoix&amp;volume=87&amp;publication_year=2002&amp;pages=825-833&amp;pmid=12373594&amp;doi=10.1038/sj.bjc.6600540&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B40-cancers-14-05305">
<span class="label">40.</span><cite>Olaussen K.A., Dunant A., Fouret P., Brambilla E., AndrÃ© F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H.H., et al.  DNA Repair by ERCC1 in Nonâ€“Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. N. Engl. J. Med. 2006;355:983â€“991. doi: 10.1056/NEJMoa060570.</cite> [<a href="https://doi.org/10.1056/NEJMoa060570" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16957145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=DNA%20Repair%20by%20ERCC1%20in%20Non%E2%80%93Small-Cell%20Lung%20Cancer%20and%20Cisplatin-Based%20Adjuvant%20Chemotherapy&amp;author=K.A.%20Olaussen&amp;author=A.%20Dunant&amp;author=P.%20Fouret&amp;author=E.%20Brambilla&amp;author=F.%20Andr%C3%A9&amp;volume=355&amp;publication_year=2006&amp;pages=983-991&amp;pmid=16957145&amp;doi=10.1056/NEJMoa060570&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B41-cancers-14-05305">
<span class="label">41.</span><cite>Vilmar A., Santoni-Rugiu E., SÃ¸rensen J. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann. Oncol. 2010;21:1817â€“1824. doi: 10.1093/annonc/mdq053.</cite> [<a href="https://doi.org/10.1093/annonc/mdq053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20332140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=ERCC1%20and%20histopathology%20in%20advanced%20NSCLC%20patients%20randomized%20in%20a%20large%20multicenter%20phase%20III%20trial&amp;author=A.%20Vilmar&amp;author=E.%20Santoni-Rugiu&amp;author=J.%20S%C3%B8rensen&amp;volume=21&amp;publication_year=2010&amp;pages=1817-1824&amp;pmid=20332140&amp;doi=10.1093/annonc/mdq053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B42-cancers-14-05305">
<span class="label">42.</span><cite>Simon G.R., Schell M.J., Begum M., Kim J., Chiappori A., Haura E., Antonia S., Bepler G. Preliminary indication of survival benefit fromERCC1andRRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer. 2012;118:2525â€“2531. doi: 10.1002/cncr.26522.</cite> [<a href="https://doi.org/10.1002/cncr.26522" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3270127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22028294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Preliminary%20indication%20of%20survival%20benefit%20fromERCC1andRRM1-tailored%20chemotherapy%20in%20patients%20with%20advanced%20nonsmall%20cell%20lung%20cancer:%20Evidence%20from%20an%20individual%20patient%20analysis&amp;author=G.R.%20Simon&amp;author=M.J.%20Schell&amp;author=M.%20Begum&amp;author=J.%20Kim&amp;author=A.%20Chiappori&amp;volume=118&amp;publication_year=2012&amp;pages=2525-2531&amp;pmid=22028294&amp;doi=10.1002/cncr.26522&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B43-cancers-14-05305">
<span class="label">43.</span><cite>Okimoto T., Tsubata Y., Tanino R., Nakao M., Hotta T., Hamaguchi M., Hamaguchi S., Araki A., Isobe T. ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent. Anticancer Res. 2021;41:2653â€“2660. doi: 10.21873/anticanres.15046.</cite> [<a href="https://doi.org/10.21873/anticanres.15046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33952496/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res.&amp;title=ERCC1%20Is%20a%20Predictive%20Biomarker%20for%20Non-small%20Cell%20Lung%20Cancer%20But%20Is%20Antibody-dependent&amp;author=T.%20Okimoto&amp;author=Y.%20Tsubata&amp;author=R.%20Tanino&amp;author=M.%20Nakao&amp;author=T.%20Hotta&amp;volume=41&amp;publication_year=2021&amp;pages=2653-2660&amp;pmid=33952496&amp;doi=10.21873/anticanres.15046&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B44-cancers-14-05305">
<span class="label">44.</span><cite>Malottki K., Popat S., Deeks J.J., Riley R.D., Nicholson A.G., Billingham L. Problems of variable biomarker evaluation in stratified medicine researchâ€”A case study of ERCC1 in non-small-cell lung cancer. Lung Cancer. 2016;92:1â€“7. doi: 10.1016/j.lungcan.2015.11.017.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2015.11.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4729317/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26775588/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Problems%20of%20variable%20biomarker%20evaluation%20in%20stratified%20medicine%20research%E2%80%94A%20case%20study%20of%20ERCC1%20in%20non-small-cell%20lung%20cancer&amp;author=K.%20Malottki&amp;author=S.%20Popat&amp;author=J.J.%20Deeks&amp;author=R.D.%20Riley&amp;author=A.G.%20Nicholson&amp;volume=92&amp;publication_year=2016&amp;pages=1-7&amp;pmid=26775588&amp;doi=10.1016/j.lungcan.2015.11.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B45-cancers-14-05305">
<span class="label">45.</span><cite>Jonsson P., Bandlamudi C., Cheng M.L., Srinivasan P., Chavan S.S., Friedman N.D., Rosen E.Y., Richards A.L., Bouvier N., Selcuklu S.D., et al.  Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571:576â€“579. doi: 10.1038/s41586-019-1382-1.</cite> [<a href="https://doi.org/10.1038/s41586-019-1382-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7048239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31292550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Tumour%20lineage%20shapes%20BRCA-mediated%20phenotypes&amp;author=P.%20Jonsson&amp;author=C.%20Bandlamudi&amp;author=M.L.%20Cheng&amp;author=P.%20Srinivasan&amp;author=S.S.%20Chavan&amp;volume=571&amp;publication_year=2019&amp;pages=576-579&amp;pmid=31292550&amp;doi=10.1038/s41586-019-1382-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B46-cancers-14-05305">
<span class="label">46.</span><cite>Diossy M., Sztupinszki Z., Borcsok J., Krzystanek M., Tisza V., Spisak S., Rusz O., Timar J., Csabai I., Fillinger J., et al.  A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures. NPJ Precis. Oncol. 2021;5:55. doi: 10.1038/s41698-021-00199-8.</cite> [<a href="https://doi.org/10.1038/s41698-021-00199-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8213828/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34145376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=NPJ%20Precis.%20Oncol.&amp;title=A%20subset%20of%20lung%20cancer%20cases%20shows%20robust%20signs%20of%20homologous%20recombination%20deficiency%20associated%20genomic%20mutational%20signatures&amp;author=M.%20Diossy&amp;author=Z.%20Sztupinszki&amp;author=J.%20Borcsok&amp;author=M.%20Krzystanek&amp;author=V.%20Tisza&amp;volume=5&amp;publication_year=2021&amp;pages=55&amp;pmid=34145376&amp;doi=10.1038/s41698-021-00199-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B47-cancers-14-05305">
<span class="label">47.</span><cite>Huang Z., Xiong G. BRCA1 expression associated with the prognostic value of platinum-based chemotherapy for stage IIâ€“IV non-small cell lung cancer: A meta-analysis. Int. J. Biol. Markers. 2022;37:170â€“177. doi: 10.1177/03936155221088882.</cite> [<a href="https://doi.org/10.1177/03936155221088882" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35404148/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Biol.%20Markers&amp;title=BRCA1%20expression%20associated%20with%20the%20prognostic%20value%20of%20platinum-based%20chemotherapy%20for%20stage%20II%E2%80%93IV%20non-small%20cell%20lung%20cancer:%20A%20meta-analysis&amp;author=Z.%20Huang&amp;author=G.%20Xiong&amp;volume=37&amp;publication_year=2022&amp;pages=170-177&amp;pmid=35404148&amp;doi=10.1177/03936155221088882&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B48-cancers-14-05305">
<span class="label">48.</span><cite>Papadaki C., Sfakianaki M., Ioannidis G., Lagoudaki E., Trypaki M., Tryfonidis K., Mavroudis D., Stathopoulos E., Georgoulias V., Souglakos J. ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. J. Thorac. Oncol. 2012;7:663â€“671. doi: 10.1097/JTO.0b013e318244bdd4.</cite> [<a href="https://doi.org/10.1097/JTO.0b013e318244bdd4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22425915/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=ERCC1%20and%20BRAC1%20mRNA%20Expression%20Levels%20in%20the%20Primary%20Tumor%20Could%20Predict%20the%20Effectiveness%20of%20the%20Second-Line%20Cisplatin-Based%20Chemotherapy%20in%20Pretreated%20Patients%20with%20Metastatic%20Non-small%20Cell%20Lung%20Cancer&amp;author=C.%20Papadaki&amp;author=M.%20Sfakianaki&amp;author=G.%20Ioannidis&amp;author=E.%20Lagoudaki&amp;author=M.%20Trypaki&amp;volume=7&amp;publication_year=2012&amp;pages=663-671&amp;pmid=22425915&amp;doi=10.1097/JTO.0b013e318244bdd4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B49-cancers-14-05305">
<span class="label">49.</span><cite>Wang L., Meng L., Wang X.-W., Ma G.-Y., Chen J.-H. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumor Biol. 2014;35:1899â€“1906. doi: 10.1007/s13277-013-1255-4.</cite> [<a href="https://doi.org/10.1007/s13277-013-1255-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24155212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tumor%20Biol.&amp;title=Expression%20of%20RRM1%20and%20RRM2%20as%20a%20novel%20prognostic%20marker%20in%20advanced%20non-small%20cell%20lung%20cancer%20receiving%20chemotherapy&amp;author=L.%20Wang&amp;author=L.%20Meng&amp;author=X.-W.%20Wang&amp;author=G.-Y.%20Ma&amp;author=J.-H.%20Chen&amp;volume=35&amp;publication_year=2014&amp;pages=1899-1906&amp;pmid=24155212&amp;doi=10.1007/s13277-013-1255-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B50-cancers-14-05305">
<span class="label">50.</span><cite>Caiola E., Salles D., Frapolli R., Lupi M., Rotella G., Ronchi A., Garassino M.C., Mattschas N., Colavecchio S., Broggini M., et al.  Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015;6:30072â€“30087. doi: 10.18632/oncotarget.5019.</cite> [<a href="https://doi.org/10.18632/oncotarget.5019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4745782/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26353932/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Base%20excision%20repair-mediated%20resistance%20to%20cisplatin%20in%20KRAS(G12C)%20mutant%20NSCLC%20cells&amp;author=E.%20Caiola&amp;author=D.%20Salles&amp;author=R.%20Frapolli&amp;author=M.%20Lupi&amp;author=G.%20Rotella&amp;volume=6&amp;publication_year=2015&amp;pages=30072-30087&amp;pmid=26353932&amp;doi=10.18632/oncotarget.5019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B51-cancers-14-05305">
<span class="label">51.</span><cite>Zhao W., Hu L., Xu J., Shen H., Hu Z., Ma H., Shu Y., Shao Y., Yin Y. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2013;71:1287â€“1295. doi: 10.1007/s00280-013-2127-8.</cite> [<a href="https://doi.org/10.1007/s00280-013-2127-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23479135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemother.%20Pharmacol.&amp;title=Polymorphisms%20in%20the%20base%20excision%20repair%20pathway%20modulate%20prognosis%20of%20platinum-based%20chemotherapy%20in%20advanced%20non-small%20cell%20lung%20cancer&amp;author=W.%20Zhao&amp;author=L.%20Hu&amp;author=J.%20Xu&amp;author=H.%20Shen&amp;author=Z.%20Hu&amp;volume=71&amp;publication_year=2013&amp;pages=1287-1295&amp;pmid=23479135&amp;doi=10.1007/s00280-013-2127-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B52-cancers-14-05305">
<span class="label">52.</span><cite>Dai J., Jiang M., He K., Wang H., Chen P., Guo H., Zhao W., Lu H., He Y., Zhou C. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer. Front. Oncol. 2021;11:708294. doi: 10.3389/fonc.2021.708294.</cite> [<a href="https://doi.org/10.3389/fonc.2021.708294" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8479169/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34604048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=DNA%20Damage%20Response%20and%20Repair%20Gene%20Alterations%20Increase%20Tumor%20Mutational%20Burden%20and%20Promote%20Poor%20Prognosis%20of%20Advanced%20Lung%20Cancer&amp;author=J.%20Dai&amp;author=M.%20Jiang&amp;author=K.%20He&amp;author=H.%20Wang&amp;author=P.%20Chen&amp;volume=11&amp;publication_year=2021&amp;pages=708294&amp;pmid=34604048&amp;doi=10.3389/fonc.2021.708294&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B53-cancers-14-05305">
<span class="label">53.</span><cite>Owen D.H., Williams T.M., Bertino E.M., Mo X., Webb A., Schweitzer C., Liu T., Roychowdhury S., Timmers C.D., Otterson G.A. Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer. 2019;134:167â€“173. doi: 10.1016/j.lungcan.2019.06.017.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2019.06.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7194132/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31319977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Homologous%20recombination%20and%20DNA%20repair%20mutations%20in%20patients%20treated%20with%20carboplatin%20and%20nab-paclitaxel%20for%20metastatic%20non-small%20cell%20lung%20cancer&amp;author=D.H.%20Owen&amp;author=T.M.%20Williams&amp;author=E.M.%20Bertino&amp;author=X.%20Mo&amp;author=A.%20Webb&amp;volume=134&amp;publication_year=2019&amp;pages=167-173&amp;pmid=31319977&amp;doi=10.1016/j.lungcan.2019.06.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B54-cancers-14-05305">
<span class="label">54.</span><cite>Wang Y., Gudikote J., Giri U., Yan J., Deng W., Ye R., Jiang W., Li N., Hobbs B.P., Wang J., et al.  RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Nonâ€“small Cell Lung Cancer. Clin. Cancer Res. 2018;24:341â€“350. doi: 10.1158/1078-0432.CCR-17-1455.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-1455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29030353/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=RAD50%20Expression%20Is%20Associated%20with%20Poor%20Clinical%20Outcomes%20after%20Radiotherapy%20for%20Resected%20Non%E2%80%93small%20Cell%20Lung%20Cancer&amp;author=Y.%20Wang&amp;author=J.%20Gudikote&amp;author=U.%20Giri&amp;author=J.%20Yan&amp;author=W.%20Deng&amp;volume=24&amp;publication_year=2018&amp;pages=341-350&amp;pmid=29030353&amp;doi=10.1158/1078-0432.CCR-17-1455&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B55-cancers-14-05305">
<span class="label">55.</span><cite>Jiang W., Jin G., Cai F., Chen X., Cao N., Zhang X., Liu J., Chen F., Wang F., Dong W., et al.  Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response. Exp. Mol. Med. 2019;51:1â€“20. doi: 10.1038/s12276-019-0209-3.</cite> [<a href="https://doi.org/10.1038/s12276-019-0209-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6389946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30804322/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp.%20Mol.%20Med.&amp;title=Extracellular%20signal-regulated%20kinase%205%20increases%20radioresistance%20of%20lung%20cancer%20cells%20by%20enhancing%20the%20DNA%20damage%20response&amp;author=W.%20Jiang&amp;author=G.%20Jin&amp;author=F.%20Cai&amp;author=X.%20Chen&amp;author=N.%20Cao&amp;volume=51&amp;publication_year=2019&amp;pages=1-20&amp;pmid=30804322&amp;doi=10.1038/s12276-019-0209-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B56-cancers-14-05305">
<span class="label">56.</span><cite>Zou N., Xie G., Cui T., Srivastava A.K., Qu M., Yang L., Wei S., Zheng Y., Wang Q.-E. DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses. Tumor Biol. 2016;37:14183â€“14191. doi: 10.1007/s13277-016-5203-y.</cite> [<a href="https://doi.org/10.1007/s13277-016-5203-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6528175/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27553023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Tumor%20Biol.&amp;title=DDB2%20increases%20radioresistance%20of%20NSCLC%20cells%20by%20enhancing%20DNA%20damage%20responses&amp;author=N.%20Zou&amp;author=G.%20Xie&amp;author=T.%20Cui&amp;author=A.K.%20Srivastava&amp;author=M.%20Qu&amp;volume=37&amp;publication_year=2016&amp;pages=14183-14191&amp;pmid=27553023&amp;doi=10.1007/s13277-016-5203-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B57-cancers-14-05305">
<span class="label">57.</span><cite>Postel-Vinay S., Vanhecke E., Olaussen K.A., Lord C., Ashworth A., Soria J.-C. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat. Rev. Clin. Oncol. 2012;9:144â€“155. doi: 10.1038/nrclinonc.2012.3.</cite> [<a href="https://doi.org/10.1038/nrclinonc.2012.3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22330686/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Rev.%20Clin.%20Oncol.&amp;title=The%20potential%20of%20exploiting%20DNA-repair%20defects%20for%20optimizing%20lung%20cancer%20treatment&amp;author=S.%20Postel-Vinay&amp;author=E.%20Vanhecke&amp;author=K.A.%20Olaussen&amp;author=C.%20Lord&amp;author=A.%20Ashworth&amp;volume=9&amp;publication_year=2012&amp;pages=144-155&amp;pmid=22330686&amp;doi=10.1038/nrclinonc.2012.3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B58-cancers-14-05305">
<span class="label">58.</span><cite>Chae Y.K., Davis A.A., Raparia K., Agte S., Pan A., Mohindra N., Villaflor V., Giles F. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Antiâ€“PD-1/PD-L1 Therapy in Nonâ€“Small-Cell Lung Cancer. Clin. Lung Cancer. 2019;20:88â€“96.e6. doi: 10.1016/j.cllc.2018.09.008.</cite> [<a href="https://doi.org/10.1016/j.cllc.2018.09.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30425022/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=Association%20of%20Tumor%20Mutational%20Burden%20With%20DNA%20Repair%20Mutations%20and%20Response%20to%20Anti%E2%80%93PD-1/PD-L1%20Therapy%20in%20Non%E2%80%93Small-Cell%20Lung%20Cancer&amp;author=Y.K.%20Chae&amp;author=A.A.%20Davis&amp;author=K.%20Raparia&amp;author=S.%20Agte&amp;author=A.%20Pan&amp;volume=20&amp;publication_year=2019&amp;pages=88-96.e6&amp;pmid=30425022&amp;doi=10.1016/j.cllc.2018.09.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B59-cancers-14-05305">
<span class="label">59.</span><cite>Chae Y.K., Anker J.F., Oh M.S., Bais P., Namburi S., Agte S., Giles F.J., Chuang J.H. Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. Sci. Rep. 2019;9:3235. doi: 10.1038/s41598-019-39594-4.</cite> [<a href="https://doi.org/10.1038/s41598-019-39594-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6397194/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30824826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Rep.&amp;title=Mutations%20in%20DNA%20repair%20genes%20are%20associated%20with%20increased%20neoantigen%20burden%20and%20a%20distinct%20immunophenotype%20in%20lung%20squamous%20cell%20carcinoma&amp;author=Y.K.%20Chae&amp;author=J.F.%20Anker&amp;author=M.S.%20Oh&amp;author=P.%20Bais&amp;author=S.%20Namburi&amp;volume=9&amp;publication_year=2019&amp;pages=3235&amp;pmid=30824826&amp;doi=10.1038/s41598-019-39594-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B60-cancers-14-05305">
<span class="label">60.</span><cite>Xiong A., Nie W., Zhou Y., Li C., Gu K., Zhang D., Chen S., Wen F., Zhong H., Han B., et al.  Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. Front. Immunol. 2021;12:708558. doi: 10.3389/fimmu.2021.708558.</cite> [<a href="https://doi.org/10.3389/fimmu.2021.708558" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8499805/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34630387/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Immunol.&amp;title=Comutations%20in%20DDR%20Pathways%20Predict%20Atezolizumab%20Response%20in%20Non-Small%20Cell%20Lung%20Cancer%20Patients&amp;author=A.%20Xiong&amp;author=W.%20Nie&amp;author=Y.%20Zhou&amp;author=C.%20Li&amp;author=K.%20Gu&amp;volume=12&amp;publication_year=2021&amp;pages=708558&amp;pmid=34630387&amp;doi=10.3389/fimmu.2021.708558&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B61-cancers-14-05305">
<span class="label">61.</span><cite>Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913â€“917. doi: 10.1038/nature03443.</cite> [<a href="https://doi.org/10.1038/nature03443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15829966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Specific%20killing%20of%20BRCA2-deficient%20tumours%20with%20inhibitors%20of%20poly(ADP-ribose)%20polymerase&amp;author=H.E.%20Bryant&amp;author=N.%20Schultz&amp;author=H.D.%20Thomas&amp;author=K.M.%20Parker&amp;author=D.%20Flower&amp;volume=434&amp;publication_year=2005&amp;pages=913-917&amp;pmid=15829966&amp;doi=10.1038/nature03443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B62-cancers-14-05305">
<span class="label">62.</span><cite>Rottenberg S., Jaspers J.E., Kersbergen A., Van Der Burg E., Nygren A.O.H., Zander S.A.L., Derksen P.W.B., De Bruin M., Zevenhoven J., Lau A., et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA. 2008;105:17079â€“17084. doi: 10.1073/pnas.0806092105.</cite> [<a href="https://doi.org/10.1073/pnas.0806092105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2579381/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18971340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc.%20Natl.%20Acad.%20Sci.%20USA&amp;title=High%20sensitivity%20of%20BRCA1-deficient%20mammary%20tumors%20to%20the%20PARP%20inhibitor%20AZD2281%20alone%20and%20in%20combination%20with%20platinum%20drugs&amp;author=S.%20Rottenberg&amp;author=J.E.%20Jaspers&amp;author=A.%20Kersbergen&amp;author=E.%20Van%20Der%20Burg&amp;author=A.O.H.%20Nygren&amp;volume=105&amp;publication_year=2008&amp;pages=17079-17084&amp;pmid=18971340&amp;doi=10.1073/pnas.0806092105&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B63-cancers-14-05305">
<span class="label">63.</span><cite>Murai J., Feng Y., Yu G.K., Ru Y., Tang S.-W., Shen Y., Pommier Y. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7:76534â€“76550. doi: 10.18632/oncotarget.12266.</cite> [<a href="https://doi.org/10.18632/oncotarget.12266" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5340226/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27708213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Resistance%20to%20PARP%20inhibitors%20by%20SLFN11%20inactivation%20can%20be%20overcome%20by%20ATR%20inhibition&amp;author=J.%20Murai&amp;author=Y.%20Feng&amp;author=G.K.%20Yu&amp;author=Y.%20Ru&amp;author=S.-W.%20Tang&amp;volume=7&amp;publication_year=2016&amp;pages=76534-76550&amp;pmid=27708213&amp;doi=10.18632/oncotarget.12266&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B64-cancers-14-05305">
<span class="label">64.</span><cite>Ray-Coquard I., Pautier P., Pignata S., PÃ©rol D., GonzÃ¡lez-MartÃ­n A., Berger R., Fujiwara K., Vergote I., Colombo N., MÃ¤enpÃ¤Ã¤ J., et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N. Engl. J. Med. 2019;381:2416â€“2428. doi: 10.1056/NEJMoa1911361.</cite> [<a href="https://doi.org/10.1056/NEJMoa1911361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31851799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Olaparib%20plus%20Bevacizumab%20as%20First-Line%20Maintenance%20in%20Ovarian%20Cancer&amp;author=I.%20Ray-Coquard&amp;author=P.%20Pautier&amp;author=S.%20Pignata&amp;author=D.%20P%C3%A9rol&amp;author=A.%20Gonz%C3%A1lez-Mart%C3%ADn&amp;volume=381&amp;publication_year=2019&amp;pages=2416-2428&amp;pmid=31851799&amp;doi=10.1056/NEJMoa1911361&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B65-cancers-14-05305">
<span class="label">65.</span><cite>De Bono J., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K.N., Sartor O., Agarwal N., Olmos D., et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020;382:2091â€“2102. doi: 10.1056/NEJMoa1911440.</cite> [<a href="https://doi.org/10.1056/NEJMoa1911440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32343890/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Olaparib%20for%20Metastatic%20Castration-Resistant%20Prostate%20Cancer&amp;author=J.%20De%20Bono&amp;author=J.%20Mateo&amp;author=K.%20Fizazi&amp;author=F.%20Saad&amp;author=N.%20Shore&amp;volume=382&amp;publication_year=2020&amp;pages=2091-2102&amp;pmid=32343890&amp;doi=10.1056/NEJMoa1911440&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B66-cancers-14-05305">
<span class="label">66.</span><cite>Swisher E.M., Kwan T.T., Oza A.M., Tinker A.V., Ray-Coquard I., Oaknin A., Coleman R.L., Aghajanian C., Konecny G.E., Oâ€™Malley D.M., et al.  Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) Nat. Commun. 2021;12:2487. doi: 10.1038/s41467-021-22582-6.</cite> [<a href="https://doi.org/10.1038/s41467-021-22582-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8093258/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33941784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat.%20Commun.&amp;title=Molecular%20and%20clinical%20determinants%20of%20response%20and%20resistance%20to%20rucaparib%20for%20recurrent%20ovarian%20cancer%20treatment%20in%20ARIEL2%20(Parts%201%20and%202)&amp;author=E.M.%20Swisher&amp;author=T.T.%20Kwan&amp;author=A.M.%20Oza&amp;author=A.V.%20Tinker&amp;author=I.%20Ray-Coquard&amp;volume=12&amp;publication_year=2021&amp;pages=2487&amp;pmid=33941784&amp;doi=10.1038/s41467-021-22582-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B67-cancers-14-05305">
<span class="label">67.</span><cite>Morgan R.D., Clamp A.R., Evans D.G.R., Edmondson R.J., Jayson G.C. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother. Pharmacol. 2018;81:647â€“658. doi: 10.1007/s00280-018-3532-9.</cite> [<a href="https://doi.org/10.1007/s00280-018-3532-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5854713/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29464354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemother.%20Pharmacol.&amp;title=PARP%20inhibitors%20in%20platinum-sensitive%20high-grade%20serous%20ovarian%20cancer&amp;author=R.D.%20Morgan&amp;author=A.R.%20Clamp&amp;author=D.G.R.%20Evans&amp;author=R.J.%20Edmondson&amp;author=G.C.%20Jayson&amp;volume=81&amp;publication_year=2018&amp;pages=647-658&amp;pmid=29464354&amp;doi=10.1007/s00280-018-3532-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B68-cancers-14-05305">
<span class="label">68.</span><cite>Fennell D.A., Lester J.F., Danson S., Blackhall F.H., Nicolson M., Nixon L.S., Porter C., Gardner G.M., White A., Griffiths G.O., et al.  A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer. J. Clin. Oncol. 2020;38:e21649. doi: 10.1200/JCO.2020.38.15_suppl.e21649.</cite> [<a href="https://doi.org/10.1200/JCO.2020.38.15_suppl.e21649" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9386392/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35990583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=A%20randomized%20phase%20II%20trial%20of%20olaparib%20maintenance%20versus%20placebo%20monotherapy%20in%20patients%20with%20chemosensitive%20advanced%20non-small%20cell%20lung%20cancer&amp;author=D.A.%20Fennell&amp;author=J.F.%20Lester&amp;author=S.%20Danson&amp;author=F.H.%20Blackhall&amp;author=M.%20Nicolson&amp;volume=38&amp;publication_year=2020&amp;pages=e21649&amp;pmid=35990583&amp;doi=10.1200/JCO.2020.38.15_suppl.e21649&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B69-cancers-14-05305">
<span class="label">69.</span><cite>Riess J.W., Redman M.W., Wheatley-Price P., Faller B.A., Villaruz L.C., Corum L.R., Gowda A.C., Srkalovic G., Osarogiagbon R.U., Baumgart M.A., et al.  A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A) J. Clin. Oncol. 2021;39:9024. doi: 10.1200/JCO.2021.39.15_suppl.9024.</cite> [<a href="https://doi.org/10.1200/JCO.2021.39.15_suppl.9024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=A%20phase%20II%20study%20of%20rucaparib%20in%20patients%20with%20high%20genomic%20LOH%20and/or%20BRCA%201/2%20mutated%20stage%20IV%20non-small%20cell%20lung%20cancer%20(Lung-MAP%20Sub-Study,%20S1900A)&amp;author=J.W.%20Riess&amp;author=M.W.%20Redman&amp;author=P.%20Wheatley-Price&amp;author=B.A.%20Faller&amp;author=L.C.%20Villaruz&amp;volume=39&amp;publication_year=2021&amp;pages=9024&amp;doi=10.1200/JCO.2021.39.15_suppl.9024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B70-cancers-14-05305">
<span class="label">70.</span><cite>Waddington T., Mambetsariev I., Pharaon R., Fricke J., Baroz A.R., Romo H., Ghanem B., Gray S., Salgia R. Therapeutic Potential of Olaparib in Combination with Pembrolizumab in a Young Patient with a Maternally Inherited BRCA2 Germline Variant: A Research Report. Clin. Lung Cancer. 2021;22:e703â€“e707. doi: 10.1016/j.cllc.2021.01.009.</cite> [<a href="https://doi.org/10.1016/j.cllc.2021.01.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8978804/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33640299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=Therapeutic%20Potential%20of%20Olaparib%20in%20Combination%20with%20Pembrolizumab%20in%20a%20Young%20Patient%20with%20a%20Maternally%20Inherited%20BRCA2%20Germline%20Variant:%20A%20Research%20Report&amp;author=T.%20Waddington&amp;author=I.%20Mambetsariev&amp;author=R.%20Pharaon&amp;author=J.%20Fricke&amp;author=A.R.%20Baroz&amp;volume=22&amp;publication_year=2021&amp;pages=e703-e707&amp;pmid=33640299&amp;doi=10.1016/j.cllc.2021.01.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B71-cancers-14-05305">
<span class="label">71.</span><cite>Jiao S., Xia W., Yamaguchi H., Wei Y., Chen M.K., Hsu J.M., Hsu J.L., Yu W.H., Du Y., Lee H.H., et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin. Cancer Res. 2017;23:3711â€“3720. doi: 10.1158/1078-0432.CCR-16-3215.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-16-3215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5511572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28167507/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=PARP%20Inhibitor%20Upregulates%20PD-L1%20Expression%20and%20Enhances%20Cancer-Associated%20Immunosuppression&amp;author=S.%20Jiao&amp;author=W.%20Xia&amp;author=H.%20Yamaguchi&amp;author=Y.%20Wei&amp;author=M.K.%20Chen&amp;volume=23&amp;publication_year=2017&amp;pages=3711-3720&amp;pmid=28167507&amp;doi=10.1158/1078-0432.CCR-16-3215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B72-cancers-14-05305">
<span class="label">72.</span><cite>Friedlaender A., Banna G., Malapelle U., Pisapia P., Addeo A. Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today? Front. Oncol. 2019;9:166. doi: 10.3389/fonc.2019.00166.</cite> [<a href="https://doi.org/10.3389/fonc.2019.00166" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6433884/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30941314/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front.%20Oncol.&amp;title=Next%20Generation%20Sequencing%20and%20Genetic%20Alterations%20in%20Squamous%20Cell%20Lung%20Carcinoma:%20Where%20Are%20We%20Today?&amp;author=A.%20Friedlaender&amp;author=G.%20Banna&amp;author=U.%20Malapelle&amp;author=P.%20Pisapia&amp;author=A.%20Addeo&amp;volume=9&amp;publication_year=2019&amp;pages=166&amp;pmid=30941314&amp;doi=10.3389/fonc.2019.00166&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B73-cancers-14-05305">
<span class="label">73.</span><cite>Owonikoko T.K., Redman M.W., Byers L.A., Hirsch F.R., Mack P.C., Schwartz L.H., Bradley J.D., Stinchcombe T.E., Leighl N.B., Al Baghdadi T., et al.  Phase 2 Study of Talazoparib in Patients with Homologous Recombination Repairâ€“Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin. Lung Cancer. 2021;22:187â€“194.e1. doi: 10.1016/j.cllc.2021.01.001.</cite> [<a href="https://doi.org/10.1016/j.cllc.2021.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8637652/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33583720/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=Phase%202%20Study%20of%20Talazoparib%20in%20Patients%20with%20Homologous%20Recombination%20Repair%E2%80%93Deficient%20Squamous%20Cell%20Lung%20Cancer:%20Lung-MAP%20Substudy%20S1400G&amp;author=T.K.%20Owonikoko&amp;author=M.W.%20Redman&amp;author=L.A.%20Byers&amp;author=F.R.%20Hirsch&amp;author=P.C.%20Mack&amp;volume=22&amp;publication_year=2021&amp;pages=187-194.e1&amp;pmid=33583720&amp;doi=10.1016/j.cllc.2021.01.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B74-cancers-14-05305">
<span class="label">74.</span><cite>Paz-Elizur T., Krupsky M., Blumenstein S., Elinger D., Schechtman E., Livneh Z. DNA Repair Activity for Oxidative Damage and Risk of Lung Cancer. JNCI J. Natl. Cancer Inst. 2003;95:1312â€“1319. doi: 10.1093/jnci/djg033.</cite> [<a href="https://doi.org/10.1093/jnci/djg033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12953085/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JNCI%20J.%20Natl.%20Cancer%20Inst.&amp;title=DNA%20Repair%20Activity%20for%20Oxidative%20Damage%20and%20Risk%20of%20Lung%20Cancer&amp;author=T.%20Paz-Elizur&amp;author=M.%20Krupsky&amp;author=S.%20Blumenstein&amp;author=D.%20Elinger&amp;author=E.%20Schechtman&amp;volume=95&amp;publication_year=2003&amp;pages=1312-1319&amp;pmid=12953085&amp;doi=10.1093/jnci/djg033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B75-cancers-14-05305">
<span class="label">75.</span><cite>Jiang Y., Dai H., Li Y., Yin J., Guo S., Lin S.-Y., McGrail D.J. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int. J. Cancer. 2019;144:1092â€“1103. doi: 10.1002/ijc.31770.</cite> [<a href="https://doi.org/10.1002/ijc.31770" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6320711/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30152517/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Cancer&amp;title=PARP%20inhibitors%20synergize%20with%20gemcitabine%20by%20potentiating%20DNA%20damage%20in%20non-small-cell%20lung%20cancer&amp;author=Y.%20Jiang&amp;author=H.%20Dai&amp;author=Y.%20Li&amp;author=J.%20Yin&amp;author=S.%20Guo&amp;volume=144&amp;publication_year=2019&amp;pages=1092-1103&amp;pmid=30152517&amp;doi=10.1002/ijc.31770&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B76-cancers-14-05305">
<span class="label">76.</span><cite>Ramalingam S.S., Blais N., Mazieres J., Reck M., Jones C.M., Juhasz E., Urban L., Orlov S., Barlesi F., Kio E., et al.  Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Nonâ€“Small Cell Lung Cancer. Clin. Cancer Res. 2017;23:1937â€“1944. doi: 10.1158/1078-0432.CCR-15-3069.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-15-3069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27803064/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Randomized,%20Placebo-Controlled,%20Phase%20II%20Study%20of%20Veliparib%20in%20Combination%20with%20Carboplatin%20and%20Paclitaxel%20for%20Advanced/Metastatic%20Non%E2%80%93Small%20Cell%20Lung%20Cancer&amp;author=S.S.%20Ramalingam&amp;author=N.%20Blais&amp;author=J.%20Mazieres&amp;author=M.%20Reck&amp;author=C.M.%20Jones&amp;volume=23&amp;publication_year=2017&amp;pages=1937-1944&amp;pmid=27803064&amp;doi=10.1158/1078-0432.CCR-15-3069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B77-cancers-14-05305">
<span class="label">77.</span><cite>Ramalingam S.S., Novello S., Guclu S.Z., Bentsion D., Zvirbule Z., Szilasi M., Bernabe R., Syrigos K., Byers L.A., Clingan P., et al.  Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J. Clin. Oncol. 2021;39:3633â€“3644. doi: 10.1200/JCO.20.03318.</cite> [<a href="https://doi.org/10.1200/JCO.20.03318" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8577684/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34436928/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Veliparib%20in%20Combination%20With%20Platinum-Based%20Chemotherapy%20for%20First-Line%20Treatment%20of%20Advanced%20Squamous%20Cell%20Lung%20Cancer:%20A%20Randomized,%20Multicenter%20Phase%20III%20Study&amp;author=S.S.%20Ramalingam&amp;author=S.%20Novello&amp;author=S.Z.%20Guclu&amp;author=D.%20Bentsion&amp;author=Z.%20Zvirbule&amp;volume=39&amp;publication_year=2021&amp;pages=3633-3644&amp;pmid=34436928&amp;doi=10.1200/JCO.20.03318&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B78-cancers-14-05305">
<span class="label">78.</span><cite>Wilkerson M.D., Schallheim J.M., Hayes D.N., Roberts P.J., Bastien R.R., Mullins M., Yin X., Miller C.R., Thorne L.B., Geiersbach K.B., et al.  Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens. J. Mol. Diagn. 2013;15:485â€“497. doi: 10.1016/j.jmoldx.2013.03.007.</cite> [<a href="https://doi.org/10.1016/j.jmoldx.2013.03.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3699698/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23701907/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Mol.%20Diagn.&amp;title=Prediction%20of%20Lung%20Cancer%20Histological%20Types%20by%20RT-qPCR%20Gene%20Expression%20in%20FFPE%20Specimens&amp;author=M.D.%20Wilkerson&amp;author=J.M.%20Schallheim&amp;author=D.N.%20Hayes&amp;author=P.J.%20Roberts&amp;author=R.R.%20Bastien&amp;volume=15&amp;publication_year=2013&amp;pages=485-497&amp;pmid=23701907&amp;doi=10.1016/j.jmoldx.2013.03.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B79-cancers-14-05305">
<span class="label">79.</span><cite>Govindan R., Lind M., Insa A., Khan S.A., Uskov D., Tafreshi A., Guclu S., Bar J., Kato T., Lee K.H., et al.  Veliparib Plus Carboplatin and Paclitaxel Versus Investigatorâ€™s Choice of Standard Chemotherapy in Patients With Advanced Nonâ€“Squamous Nonâ€“Small Cell Lung Cancer. Clin. Lung Cancer. 2022;23:214â€“225. doi: 10.1016/j.cllc.2022.01.005.</cite> [<a href="https://doi.org/10.1016/j.cllc.2022.01.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35331641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=Veliparib%20Plus%20Carboplatin%20and%20Paclitaxel%20Versus%20Investigator%E2%80%99s%20Choice%20of%20Standard%20Chemotherapy%20in%20Patients%20With%20Advanced%20Non%E2%80%93Squamous%20Non%E2%80%93Small%20Cell%20Lung%20Cancer&amp;author=R.%20Govindan&amp;author=M.%20Lind&amp;author=A.%20Insa&amp;author=S.A.%20Khan&amp;author=D.%20Uskov&amp;volume=23&amp;publication_year=2022&amp;pages=214-225&amp;pmid=35331641&amp;doi=10.1016/j.cllc.2022.01.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B80-cancers-14-05305">
<span class="label">80.</span><cite>Li A., Yi M., Qin S., Chu Q., Luo S., Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J. Hematol. Oncol. 2019;12:98. doi: 10.1186/s13045-019-0784-8.</cite> [<a href="https://doi.org/10.1186/s13045-019-0784-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6744711/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31521196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Hematol.%20Oncol.&amp;title=Prospects%20for%20combining%20immune%20checkpoint%20blockade%20with%20PARP%20inhibition&amp;author=A.%20Li&amp;author=M.%20Yi&amp;author=S.%20Qin&amp;author=Q.%20Chu&amp;author=S.%20Luo&amp;volume=12&amp;publication_year=2019&amp;pages=98&amp;pmid=31521196&amp;doi=10.1186/s13045-019-0784-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B81-cancers-14-05305">
<span class="label">81.</span><cite>Clarke J.M., Patel J.D., Robert F., Kio E.A., Thara E., Camidge D.R., Dunbar M., Nuthalapati S., Dinh M.H., Bach B.A. Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. Lung Cancer. 2021;161:180â€“188. doi: 10.1016/j.lungcan.2021.09.004.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2021.09.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34607210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Veliparib%20and%20nivolumab%20in%20combination%20with%20platinum%20doublet%20chemotherapy%20in%20patients%20with%20metastatic%20or%20advanced%20non-small%20cell%20lung%20cancer:%20A%20phase%201%20dose%20escalation%20study&amp;author=J.M.%20Clarke&amp;author=J.D.%20Patel&amp;author=F.%20Robert&amp;author=E.A.%20Kio&amp;author=E.%20Thara&amp;volume=161&amp;publication_year=2021&amp;pages=180-188&amp;pmid=34607210&amp;doi=10.1016/j.lungcan.2021.09.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B82-cancers-14-05305">
<span class="label">82.</span><cite>Fumet J.-D., Limagne E., Thibaudin M., Truntzer C., Bertaut A., Rederstorff E., Ghiringhelli F. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. BMC Cancer. 2020;20:748.  doi: 10.1186/s12885-020-07253-x.</cite> [<a href="https://doi.org/10.1186/s12885-020-07253-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7418426/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32778095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Precision%20medicine%20phase%20II%20study%20evaluating%20the%20efficacy%20of%20a%20double%20immunotherapy%20by%20durvalumab%20and%20tremelimumab%20combined%20with%20olaparib%20in%20patients%20with%20solid%20cancers%20and%20carriers%20of%20homologous%20recombination%20repair%20genes%20mutation%20in%20response%20or%20stable%20after%20olaparib%20treatment&amp;author=J.-D.%20Fumet&amp;author=E.%20Limagne&amp;author=M.%20Thibaudin&amp;author=C.%20Truntzer&amp;author=A.%20Bertaut&amp;volume=20&amp;publication_year=2020&amp;pages=748&amp;pmid=32778095&amp;doi=10.1186/s12885-020-07253-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B83-cancers-14-05305">
<span class="label">83.</span><cite>Passiglia F., Bironzo P., Righi L., ListÃ¬ A., Arizio F., Novello S., Volante M., Scagliotti G.V. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Nonâ€“small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. Clin. Lung Cancer. 2021;22:e63â€“e66. doi: 10.1016/j.cllc.2020.07.014.</cite> [<a href="https://doi.org/10.1016/j.cllc.2020.07.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32917522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Lung%20Cancer&amp;title=A%20Prospective%20Phase%20II%20Single-arm%20Study%20of%20Niraparib%20Plus%20Dostarlimab%20in%20Patients%20With%20Advanced%20Non%E2%80%93small-cell%20Lung%20Cancer%20and/or%20Malignant%20Pleural%20Mesothelioma,%20Positive%20for%20PD-L1%20Expression%20and%20Germline%20or%20Somatic%20Mutations%20in%20the%20DNA%20Repair%20Genes:%20Rationale%20and%20Study%20Design&amp;author=F.%20Passiglia&amp;author=P.%20Bironzo&amp;author=L.%20Righi&amp;author=A.%20List%C3%AC&amp;author=F.%20Arizio&amp;volume=22&amp;publication_year=2021&amp;pages=e63-e66&amp;pmid=32917522&amp;doi=10.1016/j.cllc.2020.07.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B84-cancers-14-05305">
<span class="label">84.</span><cite>Garcia-Campelo R., Arrieta O., Massuti B., Rodriguez-Abreu D., Granados A.L.O., Majem M., Vicente D., Lianes P., Bosch-Barrera J., Insa A., et al.  Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL) Lung Cancer. 2020;150:62â€“69. doi: 10.1016/j.lungcan.2020.09.018.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2020.09.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33070053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Combination%20of%20gefitinib%20and%20olaparib%20versus%20gefitinib%20alone%20in%20EGFR%20mutant%20non-small-cell%20lung%20cancer%20(NSCLC):%20A%20multicenter,%20randomized%20phase%20II%20study%20(GOAL)&amp;author=R.%20Garcia-Campelo&amp;author=O.%20Arrieta&amp;author=B.%20Massuti&amp;author=D.%20Rodriguez-Abreu&amp;author=A.L.O.%20Granados&amp;volume=150&amp;publication_year=2020&amp;pages=62-69&amp;pmid=33070053&amp;doi=10.1016/j.lungcan.2020.09.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B85-cancers-14-05305">
<span class="label">85.</span><cite>de Haan R., van der Heuvel M.M., van Diessen J., Peulen H.M., van Werkhoven E., de Langen A.J., Lalezari F., Pluim D., Verwijs-Janssen M., Vens C., et al.  Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Nonâ€“Small Cell Lung Cancer. Clin. Cancer Res. 2021;27:1256â€“1266. doi: 10.1158/1078-0432.CCR-20-2551.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-2551" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33262140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Phase%20I%20and%20Pharmacologic%20Study%20of%20Olaparib%20in%20Combination%20with%20High-dose%20Radiotherapy%20with%20and%20without%20Concurrent%20Cisplatin%20for%20Non%E2%80%93Small%20Cell%20Lung%20Cancer&amp;author=R.%20de%20Haan&amp;author=M.M.%20van%20der%20Heuvel&amp;author=J.%20van%20Diessen&amp;author=H.M.%20Peulen&amp;author=E.%20van%20Werkhoven&amp;volume=27&amp;publication_year=2021&amp;pages=1256-1266&amp;pmid=33262140&amp;doi=10.1158/1078-0432.CCR-20-2551&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B86-cancers-14-05305">
<span class="label">86.</span><cite>Ramalingam S.S., Thara E., Awad M.M., Dowlati A., Haque B., Stinchcombe T.E., Dy G.K., Spigel D.R., Lu S., Singh N.I., et al.  JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced nonâ€“small cell lung cancer. Cancer. 2022;128:65â€“74. doi: 10.1002/cncr.33885.</cite> [<a href="https://doi.org/10.1002/cncr.33885" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9293160/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34478166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=JASPER:%20Phase%202%20trial%20of%20first-line%20niraparib%20plus%20pembrolizumab%20in%20patients%20with%20advanced%20non%E2%80%93small%20cell%20lung%20cancer&amp;author=S.S.%20Ramalingam&amp;author=E.%20Thara&amp;author=M.M.%20Awad&amp;author=A.%20Dowlati&amp;author=B.%20Haque&amp;volume=128&amp;publication_year=2022&amp;pages=65-74&amp;pmid=34478166&amp;doi=10.1002/cncr.33885&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B87-cancers-14-05305">
<span class="label">87.</span><cite>Chabot P., Hsia T.-C., Ryu J.-S., Gorbunova V., Belda-Iniesta C., Ball D., Kio E., Mehta M., Papp K., Qin Q., et al.  Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: Results of a randomized, global, placebo-controlled study. J. Neuro-Oncol. 2017;131:105â€“115. doi: 10.1007/s11060-016-2275-x.</cite> [<a href="https://doi.org/10.1007/s11060-016-2275-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5258788/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27655223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Neuro-Oncol.&amp;title=Veliparib%20in%20combination%20with%20whole-brain%20radiation%20therapy%20for%20patients%20with%20brain%20metastases%20from%20non-small%20cell%20lung%20cancer:%20Results%20of%20a%20randomized,%20global,%20placebo-controlled%20study&amp;author=P.%20Chabot&amp;author=T.-C.%20Hsia&amp;author=J.-S.%20Ryu&amp;author=V.%20Gorbunova&amp;author=C.%20Belda-Iniesta&amp;volume=131&amp;publication_year=2017&amp;pages=105-115&amp;pmid=27655223&amp;doi=10.1007/s11060-016-2275-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B88-cancers-14-05305">
<span class="label">88.</span><cite>Marzio A., Kurz E., Sahni J.M., Di Feo G., Puccini J., Jiang S., Hirsch C.A., Arbini A.A., Wu W.L., Pass H.I., et al.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell. 2022;185:169â€“183.e19. doi: 10.1016/j.cell.2021.12.005.</cite> [<a href="https://doi.org/10.1016/j.cell.2021.12.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8751279/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34963055/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=EMSY%20inhibits%20homologous%20recombination%20repair%20and%20the%20interferon%20response,%20promoting%20lung%20cancer%20immune%20evasion&amp;author=A.%20Marzio&amp;author=E.%20Kurz&amp;author=J.M.%20Sahni&amp;author=G.%20Di%20Feo&amp;author=J.%20Puccini&amp;volume=185&amp;publication_year=2022&amp;pages=169-183.e19&amp;pmid=34963055&amp;doi=10.1016/j.cell.2021.12.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B89-cancers-14-05305">
<span class="label">89.</span><cite>Vendetti F.P., Lau A., Schamus S., Conrads T.P., Oâ€™Connor M.J., Bakkenist C.J. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6:44289â€“44305. doi: 10.18632/oncotarget.6247.</cite> [<a href="https://doi.org/10.18632/oncotarget.6247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4792557/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26517239/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=The%20orally%20active%20and%20bioavailable%20ATR%20kinase%20inhibitor%20AZD6738%20potentiates%20the%20anti-tumor%20effects%20of%20cisplatin%20to%20resolve%20ATM-deficient%20non-small%20cell%20lung%20cancer%20in%20vivo&amp;author=F.P.%20Vendetti&amp;author=A.%20Lau&amp;author=S.%20Schamus&amp;author=T.P.%20Conrads&amp;author=M.J.%20O%E2%80%99Connor&amp;volume=6&amp;publication_year=2015&amp;pages=44289-44305&amp;pmid=26517239&amp;doi=10.18632/oncotarget.6247&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B90-cancers-14-05305">
<span class="label">90.</span><cite>Dunne V., Ghita M., Small D.M., Coffey C.B., Weldon S., Taggart C.C., Osman S.O., McGarry C.K., Prise K.M., Hanna G.G., et al.  Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. Radiother. Oncol. 2017;124:475â€“481. doi: 10.1016/j.radonc.2017.06.025.</cite> [<a href="https://doi.org/10.1016/j.radonc.2017.06.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28697853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiother.%20Oncol.&amp;title=Inhibition%20of%20ataxia%20telangiectasia%20related-3%20(ATR)%20improves%20therapeutic%20index%20in%20preclinical%20models%20of%20non-small%20cell%20lung%20cancer%20(NSCLC)%20radiotherapy&amp;author=V.%20Dunne&amp;author=M.%20Ghita&amp;author=D.M.%20Small&amp;author=C.B.%20Coffey&amp;author=S.%20Weldon&amp;volume=124&amp;publication_year=2017&amp;pages=475-481&amp;pmid=28697853&amp;doi=10.1016/j.radonc.2017.06.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B91-cancers-14-05305">
<span class="label">91.</span><cite>Yap T.A., Krebs M.G., Postel-Vinay S., Bang Y.J., El-Khoueiry A., Abida W., Harrington K., Sundar R., Carter L., Castanon-Alvarez E., et al.  Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. Eur. J. Cancer. 2016;69:S2. doi: 10.1016/S0959-8049(16)32607-7.</cite> [<a href="https://doi.org/10.1016/S0959-8049(16)32607-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Cancer&amp;title=Phase%20I%20modular%20study%20of%20AZD6738,%20a%20novel%20oral,%20potent%20and%20selective%20ataxia%20telangiectasia%20Rad3-related%20(ATR)%20inhibitor%20in%20combination%20(combo)%20with%20carboplatin,%20olaparib%20or%20durvalumab%20in%20patients%20(pts)%20with%20advanced%20cancers&amp;author=T.A.%20Yap&amp;author=M.G.%20Krebs&amp;author=S.%20Postel-Vinay&amp;author=Y.J.%20Bang&amp;author=A.%20El-Khoueiry&amp;volume=69&amp;publication_year=2016&amp;pages=S2&amp;doi=10.1016/S0959-8049(16)32607-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B92-cancers-14-05305">
<span class="label">92.</span><cite>Sherr C.J., McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103â€“112. doi: 10.1016/S1535-6108(02)00102-2.</cite> [<a href="https://doi.org/10.1016/S1535-6108(02)00102-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12204530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=The%20RB%20and%20p53%20pathways%20in%20cancer&amp;author=C.J.%20Sherr&amp;author=F.%20McCormick&amp;volume=2&amp;publication_year=2002&amp;pages=103-112&amp;pmid=12204530&amp;doi=10.1016/S1535-6108(02)00102-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B93-cancers-14-05305">
<span class="label">93.</span><cite>Lok B.H., Gardner E.E., Schneeberger V.E., Ni A., Desmeules P., Rekhtman N., De Stanchina E., Teicher B.A., Riaz N., Powell S.N., et al.  PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin. Cancer Res. 2017;23:523â€“535. doi: 10.1158/1078-0432.CCR-16-1040.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-16-1040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5241177/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27440269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=PARP%20Inhibitor%20Activity%20Correlates%20with%20SLFN11%20Expression%20and%20Demonstrates%20Synergy%20with%20Temozolomide%20in%20Small%20Cell%20Lung%20Cancer&amp;author=B.H.%20Lok&amp;author=E.E.%20Gardner&amp;author=V.E.%20Schneeberger&amp;author=A.%20Ni&amp;author=P.%20Desmeules&amp;volume=23&amp;publication_year=2017&amp;pages=523-535&amp;pmid=27440269&amp;doi=10.1158/1078-0432.CCR-16-1040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B94-cancers-14-05305">
<span class="label">94.</span><cite>Pietanza M.C., Waqar S.N., Krug L.M., Dowlati A., Hann C.L., Chiappori A., Owonikoko T.K., Woo K.M., Cardnell R.J., Fujimoto J., et al.  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J. Clin. Oncol. 2018;36:2386â€“2394. doi: 10.1200/JCO.2018.77.7672.</cite> [<a href="https://doi.org/10.1200/JCO.2018.77.7672" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6085179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29906251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Randomized,%20Double-Blind,%20Phase%20II%20Study%20of%20Temozolomide%20in%20Combination%20With%20Either%20Veliparib%20or%20Placebo%20in%20Patients%20With%20Relapsed-Sensitive%20or%20Refractory%20Small-Cell%20Lung%20Cancer&amp;author=M.C.%20Pietanza&amp;author=S.N.%20Waqar&amp;author=L.M.%20Krug&amp;author=A.%20Dowlati&amp;author=C.L.%20Hann&amp;volume=36&amp;publication_year=2018&amp;pages=2386-2394&amp;pmid=29906251&amp;doi=10.1200/JCO.2018.77.7672&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B95-cancers-14-05305">
<span class="label">95.</span><cite>Gay C.M., Stewart C.A., Park E.M., Diao L., Groves S.M., Heeke S., Nabet B.Y., Fujimoto J., Solis L.M., Lu W., et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346â€“360.e7. doi: 10.1016/j.ccell.2020.12.014.</cite> [<a href="https://doi.org/10.1016/j.ccell.2020.12.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8143037/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33482121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Patterns%20of%20transcription%20factor%20programs%20and%20immune%20pathway%20activation%20define%20four%20major%20subtypes%20of%20SCLC%20with%20distinct%20therapeutic%20vulnerabilities&amp;author=C.M.%20Gay&amp;author=C.A.%20Stewart&amp;author=E.M.%20Park&amp;author=L.%20Diao&amp;author=S.M.%20Groves&amp;volume=39&amp;publication_year=2021&amp;pages=346-360.e7&amp;pmid=33482121&amp;doi=10.1016/j.ccell.2020.12.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B96-cancers-14-05305">
<span class="label">96.</span><cite>Cardnell R.J., Feng Y., Diao L., Fan Y.-H., Masrorpour F., Wang J., Shen Y., Mills G.B., Minna J.D., Heymach J.V., et al.  Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clin. Cancer Res. 2013;19:6322â€“6328. doi: 10.1158/1078-0432.CCR-13-1975.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-1975" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3882158/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24077350/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Proteomic%20Markers%20of%20DNA%20Repair%20and%20PI3K%20Pathway%20Activation%20Predict%20Response%20to%20the%20PARP%20Inhibitor%20BMN%20673%20in%20Small%20Cell%20Lung%20Cancer&amp;author=R.J.%20Cardnell&amp;author=Y.%20Feng&amp;author=L.%20Diao&amp;author=Y.-H.%20Fan&amp;author=F.%20Masrorpour&amp;volume=19&amp;publication_year=2013&amp;pages=6322-6328&amp;pmid=24077350&amp;doi=10.1158/1078-0432.CCR-13-1975&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B97-cancers-14-05305">
<span class="label">97.</span><cite>Sen T., Tong P., Stewart C.A., Cristea S., Valliani A., Shames D.S., Redwood A.B., Fan Y.H., Li L., Glisson B.S., et al.  CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Res. 2017;77:3870â€“3884. doi: 10.1158/0008-5472.CAN-16-3409.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-16-3409" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5563854/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28490518/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=CHK1%20Inhibition%20in%20Small-Cell%20Lung%20Cancer%20Produces%20Single-Agent%20Activity%20in%20Biomarker-Defined%20Disease%20Subsets%20and%20Combination%20Activity%20with%20Cisplatin%20or%20Olaparib&amp;author=T.%20Sen&amp;author=P.%20Tong&amp;author=C.A.%20Stewart&amp;author=S.%20Cristea&amp;author=A.%20Valliani&amp;volume=77&amp;publication_year=2017&amp;pages=3870-3884&amp;pmid=28490518&amp;doi=10.1158/0008-5472.CAN-16-3409&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B98-cancers-14-05305">
<span class="label">98.</span><cite>de Bono J., Ramanathan R.K., Mina L., Chugh R., Glaspy J., Rafii S., Kaye S., Sachdev J., Heymach J., Smith D.C., et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017;7:620â€“629. doi: 10.1158/2159-8290.CD-16-1250.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-16-1250" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5905335/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28242752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Phase%20I,%20Dose-Escalation,%20Two-Part%20Trial%20of%20the%20PARP%20Inhibitor%20Talazoparib%20in%20Patients%20with%20Advanced%20Germline%20BRCA1/2%20Mutations%20and%20Selected%20Sporadic%20Cancers&amp;author=J.%20de%20Bono&amp;author=R.K.%20Ramanathan&amp;author=L.%20Mina&amp;author=R.%20Chugh&amp;author=J.%20Glaspy&amp;volume=7&amp;publication_year=2017&amp;pages=620-629&amp;pmid=28242752&amp;doi=10.1158/2159-8290.CD-16-1250&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B99-cancers-14-05305">
<span class="label">99.</span><cite>Woll P., Gaunt P., Danson S., Steele N., Ahmed S., Mulatero C., Shah R., Bhosle J., Hodgkinson E., Watkins B., et al.  Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 2022;171:26â€“33. doi: 10.1016/j.lungcan.2022.07.007.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2022.07.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35872530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Olaparib%20as%20maintenance%20treatment%20in%20patients%20with%20chemosensitive%20small%20cell%20lung%20cancer%20(STOMP):%20A%20randomised,%20double-blind,%20placebo-controlled%20phase%20II%20trial&amp;author=P.%20Woll&amp;author=P.%20Gaunt&amp;author=S.%20Danson&amp;author=N.%20Steele&amp;author=S.%20Ahmed&amp;volume=171&amp;publication_year=2022&amp;pages=26-33&amp;pmid=35872530&amp;doi=10.1016/j.lungcan.2022.07.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B100-cancers-14-05305">
<span class="label">100.</span><cite>Atrafi F., Groen H.J., Byers L.A., Garralda E., Lolkema M.P., Sangha R.S., Viteri S., Chae Y.K., Camidge D.R., Gabrail N.Y., et al.  A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clin. Cancer Res. 2019;25:496â€“505. doi: 10.1158/1078-0432.CCR-18-2014.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-2014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30327308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=A%20Phase%20I%20Dose-Escalation%20Study%20of%20Veliparib%20Combined%20with%20Carboplatin%20and%20Etoposide%20in%20Patients%20with%20Extensive-Stage%20Small%20Cell%20Lung%20Cancer%20and%20Other%20Solid%20Tumors&amp;author=F.%20Atrafi&amp;author=H.J.%20Groen&amp;author=L.A.%20Byers&amp;author=E.%20Garralda&amp;author=M.P.%20Lolkema&amp;volume=25&amp;publication_year=2019&amp;pages=496-505&amp;pmid=30327308&amp;doi=10.1158/1078-0432.CCR-18-2014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B101-cancers-14-05305">
<span class="label">101.</span><cite>Owonikoko T.K., Dahlberg S.E., Sica G.L., Wagner L.I., Wade J.L., Srkalovic G., Lash B.W., Leach J.W., Leal T.B., Aggarwal C., et al.  Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J. Clin. Oncol. 2019;37:222â€“229. doi: 10.1200/JCO.18.00264.</cite> [<a href="https://doi.org/10.1200/JCO.18.00264" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6338394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30523756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Randomized%20Phase%20II%20Trial%20of%20Cisplatin%20and%20Etoposide%20in%20Combination%20With%20Veliparib%20or%20Placebo%20for%20Extensive-Stage%20Small-Cell%20Lung%20Cancer:%20ECOG-ACRIN%202511%20Study&amp;author=T.K.%20Owonikoko&amp;author=S.E.%20Dahlberg&amp;author=G.L.%20Sica&amp;author=L.I.%20Wagner&amp;author=J.L.%20Wade&amp;volume=37&amp;publication_year=2019&amp;pages=222-229&amp;pmid=30523756&amp;doi=10.1200/JCO.18.00264&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B102-cancers-14-05305">
<span class="label">102.</span><cite>Farago A.F., Yeap B.Y., Stanzione M., Hung Y.P., Heist R.S., Marcoux J.P., Zhong J., Rangachari D., Barbie D.A., Phat S., et al.  Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019;9:1372â€“1387. doi: 10.1158/2159-8290.CD-19-0582.</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-19-0582" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7319046/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31416802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov.&amp;title=Combination%20Olaparib%20and%20Temozolomide%20in%20Relapsed%20Small-Cell%20Lung%20Cancer&amp;author=A.F.%20Farago&amp;author=B.Y.%20Yeap&amp;author=M.%20Stanzione&amp;author=Y.P.%20Hung&amp;author=R.S.%20Heist&amp;volume=9&amp;publication_year=2019&amp;pages=1372-1387&amp;pmid=31416802&amp;doi=10.1158/2159-8290.CD-19-0582&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B103-cancers-14-05305">
<span class="label">103.</span><cite>Laird J.H., Lok B.H., Ma J., Bell A., de Stanchina E., Poirier J.T., Rudin C.M. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. Clin. Cancer Res. 2018;24:5143â€“5152. doi: 10.1158/1078-0432.CCR-18-0401.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-18-0401" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6742772/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29945991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Talazoparib%20Is%20a%20Potent%20Radiosensitizer%20in%20Small%20Cell%20Lung%20Cancer%20Cell%20Lines%20and%20Xenografts&amp;author=J.H.%20Laird&amp;author=B.H.%20Lok&amp;author=J.%20Ma&amp;author=A.%20Bell&amp;author=E.%20de%20Stanchina&amp;volume=24&amp;publication_year=2018&amp;pages=5143-5152&amp;pmid=29945991&amp;doi=10.1158/1078-0432.CCR-18-0401&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B104-cancers-14-05305">
<span class="label">104.</span><cite>Foy V., Schenk M.W., Baker K., Gomes F., Lallo A., Frese K.K., Forster M., Dive C., Blackhall F. Targeting DNA damage in SCLC. Lung Cancer. 2017;114:12â€“22. doi: 10.1016/j.lungcan.2017.10.006.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2017.10.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29173760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Targeting%20DNA%20damage%20in%20SCLC&amp;author=V.%20Foy&amp;author=M.W.%20Schenk&amp;author=K.%20Baker&amp;author=F.%20Gomes&amp;author=A.%20Lallo&amp;volume=114&amp;publication_year=2017&amp;pages=12-22&amp;pmid=29173760&amp;doi=10.1016/j.lungcan.2017.10.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B105-cancers-14-05305">
<span class="label">105.</span><cite>Lallo A., Frese K.K., Morrow C.J., Sloane R., Gulati S., Schenk M.W., Trapani F., Simms N., Galvin M., Brown S., et al.  The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clin. Cancer Res. 2018;24:5153â€“5164. doi: 10.1158/1078-0432.CCR-17-2805.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-2805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29941481/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=The%20Combination%20of%20the%20PARP%20Inhibitor%20Olaparib%20and%20the%20WEE1%20Inhibitor%20AZD1775%20as%20a%20New%20Therapeutic%20Option%20for%20Small%20Cell%20Lung%20Cancer&amp;author=A.%20Lallo&amp;author=K.K.%20Frese&amp;author=C.J.%20Morrow&amp;author=R.%20Sloane&amp;author=S.%20Gulati&amp;volume=24&amp;publication_year=2018&amp;pages=5153-5164&amp;pmid=29941481&amp;doi=10.1158/1078-0432.CCR-17-2805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B106-cancers-14-05305">
<span class="label">106.</span><cite>Gardner E.E., Lok B.H., Schneeberger V.E., Desmeules P., Miles L.A., Arnold P.K., Ni A., Khodos I., de Stanchina E., Nguyen T., et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer Cell. 2017;31:286â€“299. doi: 10.1016/j.ccell.2017.01.006.</cite> [<a href="https://doi.org/10.1016/j.ccell.2017.01.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5313262/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28196596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Chemosensitive%20Relapse%20in%20Small%20Cell%20Lung%20Cancer%20Proceeds%20through%20an%20EZH2-SLFN11%20Axis&amp;author=E.E.%20Gardner&amp;author=B.H.%20Lok&amp;author=V.E.%20Schneeberger&amp;author=P.%20Desmeules&amp;author=L.A.%20Miles&amp;volume=31&amp;publication_year=2017&amp;pages=286-299&amp;pmid=28196596&amp;doi=10.1016/j.ccell.2017.01.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B107-cancers-14-05305">
<span class="label">107.</span><cite>Barayan R., Ran X., Lok B.H. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. J. Thorac. Dis. 2020;12:6240â€“6252. doi: 10.21037/jtd.2020.03.89.</cite> [<a href="https://doi.org/10.21037/jtd.2020.03.89" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7656434/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33209463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Dis.&amp;title=PARP%20inhibitors%20for%20small%20cell%20lung%20cancer%20and%20their%20potential%20for%20integration%20into%20current%20treatment%20approaches&amp;author=R.%20Barayan&amp;author=X.%20Ran&amp;author=B.H.%20Lok&amp;volume=12&amp;publication_year=2020&amp;pages=6240-6252&amp;pmid=33209463&amp;doi=10.21037/jtd.2020.03.89&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B108-cancers-14-05305">
<span class="label">108.</span><cite>Liu J., Barry W., Birrer M., Lee J.-M., Buckanovich R., Fleming G., Rimel B., Buss M., Nattam S., Hurteau J., et al.  Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann. Oncol. 2019;30:551â€“557. doi: 10.1093/annonc/mdz018.</cite> [<a href="https://doi.org/10.1093/annonc/mdz018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6503628/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30753272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Overall%20survival%20and%20updated%20progression-free%20survival%20outcomes%20in%20a%20randomized%20phase%20II%20study%20of%20combination%20cediranib%20and%20olaparib%20versus%20olaparib%20in%20relapsed%20platinum-sensitive%20ovarian%20cancer&amp;author=J.%20Liu&amp;author=W.%20Barry&amp;author=M.%20Birrer&amp;author=J.-M.%20Lee&amp;author=R.%20Buckanovich&amp;volume=30&amp;publication_year=2019&amp;pages=551-557&amp;pmid=30753272&amp;doi=10.1093/annonc/mdz018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B109-cancers-14-05305">
<span class="label">109.</span><cite>Kaplan A.R., Gueble S.E., Liu Y., Oeck S., Kim H., Yun Z., Glazer P.M. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD. Sci. Transl. Med. 2019;11:eaav4508. doi: 10.1126/scitranslmed.aav4508.</cite> [<a href="https://doi.org/10.1126/scitranslmed.aav4508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6626544/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31092693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci.%20Transl.%20Med.&amp;title=Cediranib%20suppresses%20homology-directed%20DNA%20repair%20through%20down-regulation%20of%20BRCA1/2%20and%20RAD&amp;author=A.R.%20Kaplan&amp;author=S.E.%20Gueble&amp;author=Y.%20Liu&amp;author=S.%20Oeck&amp;author=H.%20Kim&amp;volume=11&amp;publication_year=2019&amp;pages=eaav4508&amp;pmid=31092693&amp;doi=10.1126/scitranslmed.aav4508&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B110-cancers-14-05305">
<span class="label">110.</span><cite>Cardnell R.J., Feng Y., Mukherjee S., Diao L., Tong P., Stewart C.A., Masrorpour F., Fan Y., Nilsson M., Shen Y., et al.  Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS ONE. 2016;11:e0152584.  doi: 10.1371/journal.pone.0152584.</cite> [<a href="https://doi.org/10.1371/journal.pone.0152584" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4824499/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27055253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Activation%20of%20the%20PI3K/mTOR%20Pathway%20following%20PARP%20Inhibition%20in%20Small%20Cell%20Lung%20Cancer&amp;author=R.J.%20Cardnell&amp;author=Y.%20Feng&amp;author=S.%20Mukherjee&amp;author=L.%20Diao&amp;author=P.%20Tong&amp;volume=11&amp;publication_year=2016&amp;pages=e0152584&amp;pmid=27055253&amp;doi=10.1371/journal.pone.0152584&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B111-cancers-14-05305">
<span class="label">111.</span><cite>Shen J., Zhao W., Ju Z., Wang L., Peng Y., Labrie M., Yap T.A., Mills G.B., Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res. 2019;79:311â€“319. doi: 10.1158/0008-5472.CAN-18-1003.</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-18-1003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6588002/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30482774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.&amp;title=PARPi%20Triggers%20the%20STING-Dependent%20Immune%20Response%20and%20Enhances%20the%20Therapeutic%20Efficacy%20of%20Immune%20Checkpoint%20Blockade%20Independent%20of%20BRCAness&amp;author=J.%20Shen&amp;author=W.%20Zhao&amp;author=Z.%20Ju&amp;author=L.%20Wang&amp;author=Y.%20Peng&amp;volume=79&amp;publication_year=2019&amp;pages=311-319&amp;pmid=30482774&amp;doi=10.1158/0008-5472.CAN-18-1003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B112-cancers-14-05305">
<span class="label">112.</span><cite>Thomas A., Vilimas R., Trindade C., Erwin-Cohen R., Roper N., Xi L., Krishnasamy V., Levy E., Mammen A., Nichols S., et al.  Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. J. Thorac. Oncol. 2019;14:1447â€“1457. doi: 10.1016/j.jtho.2019.04.026.</cite> [<a href="https://doi.org/10.1016/j.jtho.2019.04.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6660419/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31063862/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Thorac.%20Oncol.&amp;title=Durvalumab%20in%20Combination%20with%20Olaparib%20in%20Patients%20with%20Relapsed%20SCLC:%20Results%20from%20a%20Phase%20II%20Study&amp;author=A.%20Thomas&amp;author=R.%20Vilimas&amp;author=C.%20Trindade&amp;author=R.%20Erwin-Cohen&amp;author=N.%20Roper&amp;volume=14&amp;publication_year=2019&amp;pages=1447-1457&amp;pmid=31063862&amp;doi=10.1016/j.jtho.2019.04.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B113-cancers-14-05305">
<span class="label">113.</span><cite>Peyraud F., Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers. 2020;12:1502.  doi: 10.3390/cancers12061502.</cite> [<a href="https://doi.org/10.3390/cancers12061502" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7352466/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32526888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Combined%20PARP%20Inhibition%20and%20Immune%20Checkpoint%20Therapy%20in%20Solid%20Tumors&amp;author=F.%20Peyraud&amp;author=A.%20Italiano&amp;volume=12&amp;publication_year=2020&amp;pages=1502&amp;pmid=32526888&amp;doi=10.3390/cancers12061502&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B114-cancers-14-05305">
<span class="label">114.</span><cite>Wu Z., Tao H., Zhang S., Wang X., Ma J., Li R., Liu Z., Wang J., Cui P., Chen S., et al.  Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. Cancer Immunol. Immunother. 2021;70:2971â€“2980. doi: 10.1007/s00262-021-02852-4.</cite> [<a href="https://doi.org/10.1007/s00262-021-02852-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8423634/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33740125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol.%20Immunother.&amp;title=Efficacy%20and%20safety%20of%20anti-PD-1-based%20therapy%20in%20combination%20with%20PARP%20inhibitors%20for%20patients%20with%20advanced%20solid%20tumors%20in%20a%20real-world%20setting&amp;author=Z.%20Wu&amp;author=H.%20Tao&amp;author=S.%20Zhang&amp;author=X.%20Wang&amp;author=J.%20Ma&amp;volume=70&amp;publication_year=2021&amp;pages=2971-2980&amp;pmid=33740125&amp;doi=10.1007/s00262-021-02852-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/9654807/bin/cancers-14-05305-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">Click here for additional data file.</a><sup> (144.4KB, zip) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cancers are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/cancers14215305"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/cancers-14-05305.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (906.8Â KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/9654807/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/9654807/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC9654807%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC9654807/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC9654807/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC9654807/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/36358724/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC9654807/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/36358724/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC9654807/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/9654807/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="AeOph8e0Ooj2rf9unH7k4WbE2ysIgOoUcoeC30Hy56NmClEvDGvUB44k9qRVjzTp">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
